Mutant HTT seeding activity: a marker of disease progression and neurotoxicity in models of Huntington’s disease by Morton, Jennifer et al.
	 1	
Mutant HTT seeding activity: a marker of disease progression and 
neurotoxicity in models of Huntington’s disease 
Anne Ast1,8, Alexander Buntru1,8, Franziska Schindler1,8, Regine Hasenkopf1, Aline 
Schulz1, Lydia Brusendorf1, Konrad Klockmeier1, Gerlinde Grelle1, Benjamin 
McMahon1, Hannah Niederlechner1, Isabelle Jansen1, Lisa Maria Diez1, Annett 
Boeddrich1, Sophie A. Franklin2, Barbara Baldo3, Sigrid Schnoegl1, Severine Kunz4, 
Bettina Purfürst4, Harm H. Kampinga5, A. Jennifer Morton6, Åsa Petersén3, Janine 
Kirstein7, Gillian P. Bates2, Erich E. Wanker1* 
1 Neuroproteomics, Max Delbrueck Center for Molecular Medicine, 13125 Berlin, 
Germany and Berlin Institute of Health (BIH), 10178 Berlin, Germany 
2 Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London 
WC1N 3BG, United Kingdom 
3 Translational Neuroendocrine Research Unit, Department of Experimental Medical 
Science, Lund University, Lund, Sweden 
4 Electron Microscopy Platform, Max Delbrueck Center for Molecular Medicine, 
Berlin, Germany 
5 Department of Cell Biology, University Medical Center Groningen, 9713 GZ 
Groningen, the Netherlands  
6 Department of Physiology, Development and Neuroscience, University of 
Cambridge, Cambridge CB2 3DY, United Kingdom 
7 Proteostasis in Aging and Disease, Leibniz-Institute for Molecular Pharmacology 
(FMP), Berlin, Germany 
  
8 Co-first author 
 
* Correspondence: ewanker@mdc-berlin.de  
	 2	
 
SUMMARY 
Self-propagating, amyloidogenic mutant huntingtin (HTT) aggregates may 
drive progression of Huntington’s disease (HD). Here, we report the development of a 
FRET-based HTT aggregate seeding (FRASE) biosensor assay that enables the 
quantification of mutant HTT seeding activity (HSA) in complex biosamples from HD 
patients and disease models. Application of the FRASE assay revealed HSA in brain 
homogenates of presymptomatic HD transgenic and knock-in mice and its 
progressive increase with phenotypic changes, suggesting that HSA quantitatively 
tracks disease progression. Biochemical investigations of mouse brain homogenates 
demonstrated that HSA is high in fractions that contain small HTT fibrils but is low in 
fractions with large, insoluble HTT aggregates, indicating that small rather than large 
mutant HTT structures possess HSA. Finally, we assessed the neurotoxicity of 
mutant HTT seeds in an inducible Drosophila model transgenic for HTT. We found a 
strong correlation between HSA measured in adult neurons and the increased 
mortality of transgenic HD flies, indicating that FRASE assays detect disease-
relevant, neurotoxic, mutant HTT structures with severe phenotypic consequences in 
vivo. 
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INTRODUCTION 
Self-propagating protein aggregates are a pathological hallmark of a large 
number of neurodegenerative diseases including Huntington’s disease (HD) (Jucker 
and Walker, 2013; Soto, 2012; Chiti et al., 2017). Recent studies indicate that 
aggregate pathology and associated tissue atrophy do not appear randomly 
throughout the brain but instead progress along distinct neuronal networks (Brundin 
et al., 2010; Goedert, 2015). Evidence was provided that amyloidogenic protein 
assemblies spread from cell to cell, converting free molecules of the same protein 
into aggregated species. This transcellular propagation may drive pathogenesis in 
neurodegenerative diseases (Guo and Lee, 2014; Meyer-Luehmann et al., 2006; 
Pecho-Vrieseling et al., 2014; Peelaerts et al., 2015). To understand the mechanisms 
of disease development and progression, it is of critical importance to specifically 
monitor the activity of self-propagating protein aggregates in complex biosamples. 
A number of cell-free and cell-based assays have been established that allow 
the quantification of seeding activity of amyloidogenic aggregates in crude protein 
homogenates (Atarashi et al., 2007; Castilla et al., 2006; Holmes et al., 2014; 
Salvadores et al., 2014; Tan et al., 2015). These methods take advantage of the 
phenomenon that ordered protein aggregates are spontaneously formed from 
monomers by a nucleation-dependent process (Jarrett and Lansbury, 1993; 
Scherzinger et al., 1999), a relatively slow process in vitro. However, spontaneous 
amyloid formation can be accelerated by the addition of preformed aggregates that 
function as templates or seeds for the conversion of monomers from a soluble into an 
aggregated state (Cohen et al., 2012; Colby et al., 2007; Jarrett and Lansbury, 1993). 
Biosamples that contain seeding-competent protein aggregates might therefore 
stimulate the polymerization of soluble amyloidogenic proteins with related amino 
acid sequences in cell-free or cell-based seeding assays.  
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Based on this premise, the protein misfolding cyclic amplification (PMCA) 
technology and related cell-free methods (Atarashi et al., 2007; Atarashi et al., 2011; 
Saborio et al., 2001) have been developed, which allow the detection of minute 
quantities of seeding-competent PrPSc aggregates in various biomaterials prepared 
from patients or rodent models with prion disease (Castilla et al., 2005; Colby et al., 
2007; Saa et al., 2006). Variants of the PMCA technology have also been applied for 
the amplification of amyloid-β, α-synuclein and HTT aggregates from biosamples (Du 
et al., 2011; Herva et al., 2014; Salvadores et al., 2014). A key feature of PMCA 
methods is that seed-mediated amyloid polymerization is indirectly monitored through 
the reporter dye Thioflavin T (ThT), which changes its fluorescence emission upon 
binding to ordered amyloid fibrils (Biancalana and Koide, 2010; LeVine, 1993). Also 
cell-based amyloid polymerization assays have been developed (Holmes et al., 2014; 
Tan et al., 2015). In these assays, ectopically expressed aggregation-prone reporter 
proteins with fluorescent tags such as ECFP or EYFP are generally utilized as 
biosensors for detecting amyloidogenic protein aggregates.  
Recent studies with brain slices, cellular, fly and mouse models provide 
evidence that mutant HTT aggregates with pathogenic polyQ tracts indeed possess 
seeding activity and spread from cell to cell (Ren et al., 2009; Pecho-Vrieseling et al., 
2014; Babcock and Ganetzky, 2015; Pearce et al., 2015), suggesting that 
proteopathic HTT seeding in HD patient brains or mouse models represents a causal 
process that drives pathogenesis (Brundin et al., 2010; Jeon et al., 2016). However, it 
currently remains unclear whether mutant HTT seeding is indeed responsible for 
dysfunction and neurodegeneration in disease. While several HTT aggregate 
species, i.e. small oligomers, protofibrils and large fibrillar structures, have been 
described as potentially pathogenic (Kim et al., 2016; Nucifora et al., 2012; Pieri et 
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al., 2012; Scherzinger et al., 1997), the HTT species that exhibit seeding activity in 
vivo still need to be pinpointed.  
To be regarded as disease relevant, we propose that seeding-competent HTT 
aggregates need to be detectable in affected brain regions in patients and transgenic 
HD mouse models. To promote disease development, such structures should be 
present in model systems prior to the appearance of a disease phenotype. Also, their 
abundance in affected tissues should increase with the severity of disease 
symptoms. Finally, perturbation of mutant HTT seeding activity either through genetic 
manipulation or chemical compounds that target seeding-competent structures 
should influence the disease phenotype in model systems. In summary, to elucidate 
the potential importance of mutant HTT seeding in disease, it is crucial to (1) detect 
seeding-competent structures in relevant biosamples with high sensitivity and 
specificity, and (2) to investigate their potential impact on biological functions and 
phenotypes in well-characterized model systems. 
Here, we describe the development of a FRET-based HTT aggregate seeding 
(FRASE) assay, which allows the quantification of mutant HTT seeding activity (HSA) 
in complex biosamples with high sensitivity and specificity. Application of the method 
revealed HSA in disease-affected brain tissues of HD patients and mouse models. 
Furthermore, we observed HSA in brain homogenates of presymptomatic HD mice 
and its progressive increase with disease development. Biochemical investigations of 
mouse brain homogenates revealed high HSA predominantly in soluble protein 
fractions that contain small, fibrillar HTT structures, suggesting that small rather than 
large HTT aggregates are responsible for this activity in vivo. Finally, using an 
inducible Drosophila model of HD, we demonstrated that the formation of small, 
seeding-competent HTTex1Q97 structures in adult neurons is associated with a 
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reduced lifespan of transgenic flies, indicating that FRASE assays detect neurotoxic 
structures. The potential implications of our results for the development of diagnostic 
tools and therapeutic strategies for HD and other polyglutamine diseases are 
discussed. 
 
RESULTS 
Establishment of a FRET-based HTT aggregate seeding assay with 
recombinant fibrillar Ex1Q48 aggregates 
To monitor the seeding activity of mutant HTT aggregates in biosamples, we 
first developed a cell-free HTT aggregation assay with recombinant fluorescent 
reporter proteins (Figure S1A). Two soluble glutathione S-transferase HTT exon-1 
fusion proteins with 48 glutamines C-terminally fused to CyPet or YPet (GST-
Ex1Q48-CyPet or -YPet) were produced in E. coli and purified to ~90% homogeneity 
using glutathione sepharose chromatography (Figure S1B).  
Next, the recombinant proteins were cleaved with the sequence-specific 
PreScission protease (PSP) in order to release GST and to initiate the spontaneous 
aggregation of the fusion proteins Ex1Q48-CyPet and -YPet in vitro. The assembly of 
the tagged HTT exon-1 (HTTex1) proteins into insoluble aggregates over time was 
monitored using an established membrane filter retardation assay (FRA), which 
detects large HTTex1 aggregates but not monomers or small oligomers (Wanker et 
al., 1999; PMID: 29856013). We found that the fusion proteins Ex1Q48-CyPet and -
YPet rapidly self-assemble into SDS-stable aggregates after a lag phase of 4-5 h 
(Figure 1A), indicating that the C-terminal fluorescent tags (Figure S1A) do not 
prevent the formation of stable, insoluble HTTex1 aggregates. Similar results were 
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obtained when the untagged fusion protein GST-Ex1Q48 (Figure S1A) was cleaved 
with PSP and the time-dependent formation of Ex1Q48 aggregates was monitored by 
FRA, confirming recently reported results (PMID: 29601786). 
To investigate the morphology of spontaneously formed Ex1Q48-CyPet and -
YPet aggregates, we analyzed the aggregation reactions with atomic force 
microscopy (AFM). After 24 h, we observed that the released CyPet- and YPet-
tagged Ex1Q48 fusion proteins, similar to the untagged Ex1Q48 protein, form typical 
fibrillar protein aggregates (Figure 1B).  
 Next, we hypothesized that the aggregation of CyPet- and YPet-tagged 
HTTex1 fragments should lead to a time-dependent increase of FRET as the 
fluorescent tags are brought in close proximity when fibrillar aggregates are formed 
(Figure 1C). We treated mixtures of the GST-Ex1Q48-CyPet/-YPet fusion proteins 
(1:1 molar ratio; 1 – 3 µM concentrations) with PSP and quantified the spontaneous 
formation of Ex1Q48-CyPet/-YPet co-aggregates by repeated FRET measurements 
in a 384-well microtiter plate. We observed a time- and concentration-dependent 
increase of FRET efficiency (Figure 1D), confirming previous observations that 
amyloidogenic polyQ-containing HTTex1 fragments form stable co-aggregates in cell-
free assays (Busch et al., 2003). In contrast, no time-dependent increase of FRET 
efficiency was observed in samples that were not treated with PSP (Figure 1D), 
underlining that the removal of the GST tag from the fusion proteins and the release 
of CyPet- and YPet-tagged Ex1Q48 fragments is critical for the self-assembly of co-
aggregates. Proteolytic cleavage of the GST fusion proteins with PSP was confirmed 
by SDS-PAGE and immunoblotting (Figure S1C). AFM analysis confirmed that the 
samples indeed contain typical fibrillar HTTex1 co-aggregates (Figure S1D). 
Together, these experiments indicate that the time-dependent increase of FRET is 
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the result of the spontaneous formation of fibrillar Ex1Q48-CyPet/-YPet co-
aggregates in vitro (Figure 1C and S1D). 
 In order to assess whether preformed fibrillar Ex1Q48 aggregates (Figure 1B), 
can seed the polymerization of the reporter fusion proteins Ex1Q48-CyPet/-YPet, we 
incubated a 1:1 mixture of the fusion proteins (1.2 µM total concentration) with PSP 
and different amounts of preformed Ex1Q48 fibrils as seeds and monitored the 
polymerization of the reporter proteins through quantification of FRET. We observed 
that addition of fibrils to aggregation reactions shortens the lag phase of Ex1Q48-
CyPet/-YPet polymerization in a concentration-dependent manner (Figure 1E and 
1F), indicating that the added fibrillar HTTex1 aggregates possess seeding activity. 
We termed the established method, which permits the quantification of mutant HTT 
seeding activity (HSA) in samples of interest, FRET-based HTT aggregate seeding 
(FRASE) assay. 
In independent control experiments, we also investigated whether a mixture of 
fusion proteins with polyQ tracts of a non-pathogenic length, GST-Ex1Q23-CyPet/-
YPet (Figure S1A), can also be applied as reporter molecules to monitor HSA. We 
found that preformed, fibrillar Ex1Q48 seeds (Figure 1B) cannot induce FRET when 
they are added with PSP to GST-Ex1Q23-CyPet/-YPet reactions (Figure S1E), 
indicating that reporter molecules with pathogenic polyQ tracts are required to 
efficiently monitor HSA. Finally, we confirmed that addition of proteolytically cleaved 
GST-Ex1Q23 fusion protein as well as of uncleaved GST-Ex1Q23 or GST-Ex1Q48 
fusion proteins do not shorten the lag phase of Ex1Q48-CyPet/-YPet polymerization 
(Figure S1F). 
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Both small fibrillar Ex1Q48 seeds and large bundles of fibrillar aggregates 
exhibit HSA in FRASE assays  
 Our initial experiments indicated that large bundles of preformed fibrillar 
Ex1Q48 aggregates (~1-2 µm in length; Figure 1B) can promote the polymerization 
of Ex1Q48-CyPet/-YPet fusions in FRASE assays (Figure 1E and 1F). Next, we 
investigated whether small fibrillar Ex1Q48 structures, which can be obtained from 
large fibril bundles through sonication (Scherzinger et al., 1999), possess HSA. We 
sonicated preformed fibrillar Ex1Q48 aggregates (Figure 1B) for 1, 2, 5, 10, 30 and 
60 seconds on ice and subsequently determined the seeding activities of the 
generated fractions using FRASE assays. We found that sonication reveals Ex1Q48 
preparations with increased seeding activity (Figure S2A and S2B), indicating that 
besides large fibrillar aggregates also small Ex1Q48 structures, which increase in 
their abundance through sonication-induced fibril breakage (Cohen et al., 2013; 
Scherzinger et al., 1999), possess high seeding activity. 
 To confirm that smaller Ex1Q48 assemblies are produced through sonication, 
we compared the sonicated and non-sonicated samples using the FRA (Wanker et 
al., 1999). We found that the fibrillar Ex1Q48 aggregates in non-sonicated samples 
are efficiently retained on filter membranes (Figure S2C), while the HTTex1 
structures in sonicated samples (>30s) are not.  
Next, the sonicated and non-sonicated samples were analyzed using dot blot 
(DB) assays, which allow the identification of protein assemblies under native 
conditions on filter membranes independent of their size (Kayed et al., 2003). These 
experiments revealed Ex1Q48 immunoreactivity in both sonicated and non-sonicated 
samples (Figure S2C), confirming that sonication (>30s) leads to fibril breakage and 
the formation of small, soluble HTTex1 structures. Finally, we analyzed the generated 
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samples with AFM, confirming that sonication leads to the formation of small fibrillar 
Ex1Q48 structures (Figure S2D) and supporting the results obtained with denaturing 
FRAs (Figure S2C).  
 
FRASE assays detect recombinant Ex1Q48 seeds with high sensitivity and 
specificity 
To determine the sensitivity and the dynamic range of the FRASE assay, we 
first generated small Ex1Q48 seeds through sonication of preformed Ex1Q48 fibrils 
for 60 sec on ice. Analysis with blue native PAGE and immunoblotting confirmed that 
smaller Ex1Q48 structures with an average molecular weight of ~1,250 kDa 
(~90mers) were indeed produced through sonication (Figure 2A). As mentioned 
above, the non-sonicated fibrils (Figure 1B) were much larger in size and were 
retained in the pockets of blue native gels.  
Next, a range of concentrations (0.001 – 1111.1 pM) of Ex1Q48 seeds were 
analyzed for their potency to stimulate Ex1Q48-CyPet/-YPet polymerization in 
FRASE assays. As expected, we observed a robust and dose-dependent shortening 
of the lag phase when sonicated Ex1Q48 structures were added to polymerization 
reactions (Figure 2B and 2C). We determined a threshold of ~60 fM for detecting 
small Ex1Q48 seeds. We observed that FRASE assays respond quantitatively to the 
addition of sonicated Ex1Q48 seeds over a dynamic range of more than 4 orders of 
magnitude (Figure 2B and 2C). At a concentration of ~560 fM the Z’ factor, indicative 
of a robust assay when greater than 0.5 (Zhang et al., 1999), was 0.67 (Figure 2C). 
Finally, we investigated the specificity of the FRASE assay for detecting 
HTTex1 aggregates. We produced fibrillar aggregates of the polypeptides α-
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synuclein, tau, amyloid-β and IAPP in vitro and analyzed these structures for their 
potential to stimulate the polymerization of the reporter proteins Ex1Q48-CyPet/-YPet 
in FRASE assays. The unrelated fibrillar aggregates did not significantly diminish the 
lag phase of spontaneous Ex1Q48-CyPet/-YPet polymerization (Figure 2D), 
indicating that the FRASE assay specifically detects amyloidogenic HTTex1 
aggregates. AFM analysis confirmed that fibrillar α-synuclein, tau, amyloid-β and 
IAPP aggregates were used (Figure 2E).  
 
Mutant HTT seeding activity is detectable in brains of HD mice and patients  
 To investigate whether the FRASE assay enables the detection of mutant HSA 
in complex biosamples (Figure 3A), we first assessed crude brain homogenates 
prepared from 12-week-old R6/2Q212 transgenic mice (carrying ~212 CAGs) and 
age-matched controls. R6/2Q212 mice express low levels of the human HTTex1 
protein with a very long polyQ tract and are a model for the aberrant HTT splicing that 
occurs in HD (Sathasivam et al., 2013). They show motor abnormalities from 8 weeks 
of age (Carter et al., 1999; Lione et al., 1999) and typical HTT inclusion bodies from 
3-4 weeks onwards (Li et al., 1999), suggesting that brains of 12-week-old mice 
should contain HTT species displaying HSA. We detected high levels of HSA in 
crude brain homogenates of R6/2Q212 mice but not in those of age-matched 
littermate controls (Figures 3B and 3C), indicating the presence of seeding-
competent HTTex1 structures. Independent control experiments with the non-
pathogenic reporter molecules Ex1Q23-CyPet/-YPet did not reveal detectable HSA in 
R6/2Q212 brain homogenates (Figure S3A), confirming our initial results (Figure 
S1E) that pathogenic polyQ tracts in reporter molecules are critical to efficiently 
monitor HSA. 
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Next, we assessed whether HSA is detectable in brain extracts of 12-week-old 
R6/2Q51 (Larson et al., 2015) mice, which express a mutant HTTex1 fragment with a 
polyQ tract of 51 glutamines (R6/2Q51). In comparison to R6/2Q212 mice, these 
mice do not yet have a disease phenotype at 12 weeks of age, suggesting that HSA 
should be lower. FRASE analysis revealed that brain homogenates of prodromal 12-
week-old R6/2Q51 mice do not possess significant HSA (Figure S3B). However, 
activity was detectable in extracts of very old R6/2Q51 mice (104-105 weeks), which 
show signs of disease (unpublished data, AJM).  
 We next investigated whether HSA is detectable in the hypothalamus of 
mouse brains, in which the proteins HTT853-Q79 or HTT853-Q18 were 
overexpressed for 8 weeks using viral vectors. Previous studies have demonstrated 
that hypothalamic expression of HTT853-Q79 for 6 weeks leads to a dramatic gain of 
body weight and the formation of insoluble HTT protein aggregates (Hult et al., 
2011). We found that HTT853-Q79 mice were significantly heavier than control and 
HTT853-Q18 mice (Figure S3C), confirming previous results (Baldo et al., 2013). We 
also observed a significantly higher HSA in brain homogenates of HTT853-Q79 
compared to HTT853-Q18 mice and controls (Figure S3D), indicating that the 
abundance of seeding-competent mutant HTT conformers in specific mouse brain 
regions is associated with an increase in body weight. 
We next examined whether HSA can be detected in affected brain regions of 
HD patients. Crude protein extracts prepared from cerebral cortex, caudate nucleus 
and cerebellum of postmortem patients and control individuals were systematically 
analyzed using the FRASE assay. Strikingly, HSA was invariably detected in HD but 
not in control samples (Figure 3D), indicating that the method is suitable to 
discriminate between patients and healthy individuals. Interestingly, HSA was 
	 13	
detectable in the cerebral cortex and the caudate nucleus, which contain neuronal 
inclusions and are severely affected in HD patients (Zuccato et al., 2010) while it was 
not observed in the cerebellum, which does not exhibit typical neuronal HTT 
inclusions (DiFiglia et al., 1997). Similarly, no HSA was detectable in postmortem 
brains of patients with Alzheimer’s disease (AD) (Figure S3E) that typically contain 
fibrillar amyloid-β and tau aggregates (Goedert, 2015).  
Finally, we were interested to clarify whether HSA in biosamples indeed 
originates from mutant HTT seeds. We produced brain extracts from symptomatic 12-
week-old R6/2Q212 mice and littermate controls and immunodepleted potential 
mutant HTTex1 seeds using the monoclonal anti-HTT antibody MW8 (Ko et al., 
2001), before systematic FRASE analysis. We observed a dramatic decrease of HSA 
in MW8-immunodepleted R6/2Q212 brain homogenates but not in homogenates 
treated with an isotype control antibody (Figures S4A and S4B), indicating that 
seeding-competent HTTex1 aggregates can be efficiently removed from R6/2Q212 
mouse brain extracts by MW8 antibody treatment. As expected, we did not detect 
HSA in crude brain extracts of age-matched wild-type control mice (Figures S4A and 
S4B). SDS-PAGE and immunoblotting confirmed depletion of HTTex1 protein 
aggregates from brain homogenates by MW8 antibody treatment (Figures S4C and 
S4D).  
 
FRASE assay detects mutant HSA in brains of presymptomatic HD transgenic 
and knock-in mice 
 To address whether seeding-competent mutant HTTex1 aggregates are 
detectable in brains of presymptomatic HD transgenic mice, we first analyzed non-
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sonicated brain homogenates of young R6/2Q212 mice and age-matched controls 
using the FRASE assay. We detected significant HSA in brain extracts of 2-week-old 
R6/2Q212 mice (Figure 3E) that progressively increased over time. This result was 
also obtained with sonicated brain extracts (Figure 3F). With sonication, significant 
HSA was already detectable in brains of 1-day-old R6/2Q212 transgenic mice, 
indicating that seeding-competent HTTex1 structures are present in brains of 
R6/2Q212 mice long before inclusion bodies or motor abnormities can be detected 
(Davies et al., 1997; Zuccato et al., 2010). 
Next, we investigated whether HSA is detectable in presymptomatic HdhQ150 
knock-in mice that express a full-length HTT protein with a pathogenic polyQ tract of 
~150 glutamines (Lin et al., 2001). These mice develop symptoms much more slowly 
than R6/2Q212 mice (Mangiarini et al., 1996; Zuccato et al., 2010). They show onset 
of depressive-like symptoms by 12 months of age (Ciamei et al., 2015) and 
impairment of motor function at ~18 months of age. Widespread deposition of 
insoluble HTT aggregates throughout the brain is observed by ~22 months of age 
(Woodman et al., 2007). We systematically analyzed tissue homogenates prepared 
from cortex, striatum and hippocampus of 2-, 5- and 8-month-old heterozygous 
HdhQ150 mice and littermate controls using the FRASE assay. We observed 
progressively increasing HSA in protein extracts from all three brain regions of 
HdhQ150 but not from control mice (Figure 3G), confirming that mutant HTT seeds 
are detectable in HD mouse brains long before the appearance of neuronal inclusion 
bodies and motor abnormalities (Woodman et al., 2007).  
 
HSA is detectable in soluble protein fractions after depletion of large, insoluble 
HTT aggregates by centrifugation  
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 To investigate whether HSA in transgenic HD mouse brains originates 
predominantly from soluble or insoluble HTT aggregates, non-sonicated brain 
homogenates prepared from symptomatic 12-week-old R6/2Q212 mice were 
centrifuged for 20 min at 2,700 x g (low speed) or 18,000 x g (medium speed), 
respectively, and the resulting supernatant and pellet fractions (S1Low, P1Low and 
S1Med, P1Med; Figure 4A) were analyzed with FRASE assays. Interestingly, HSA was 
high in the parental crude lysate and in the S1Low fraction, while it was relatively low 
in the P1Low fraction (Figure 4B), suggesting that it predominantly originates from 
soluble rather than insoluble HTTex1 aggregates. A similar result was obtained when 
the fractions S1Med and P1Med were analyzed (Figure 4B). However, after medium 
speed centrifugation HSA in the P1Med fraction was higher than in the P1Low fraction, 
indicating that mutant HTTex1 seeds can be removed from the brain homogenate 
using a higher centrifugation speed. This trend was even more pronounced when the 
generated S1Med fraction was subjected to a high-speed centrifugation (190,000 x g), 
resulting in the supernatant and pellet fractions S2 and P2 (Figure 4A). FRASE 
analysis revealed a significantly higher HSA in the P2 than in the S2 fraction, 
indicating that small seeding-competent HTTex1 aggregates can be removed from 
the soluble S1Med fraction by high speed centrifugation (Figures 4A and B). 
To obtain a first hint about the size of the seeding-competent HTTex1 
aggregates in the brains of R6/2Q212 mice, the supernatant and pellet fractions were 
analyzed using the established FRA (Wanker et al., 1999). We found HTTex1 
immunoreactivity predominantly in the P1Low and P1Med fractions. In comparison, 
weak immunoreactivity was detected in the S1Low and no activity in the S1Med, P2 and 
S2 fractions (Figure 4C), indicating that HSA in R6/2Q212 mouse brains 
predominately originates from small, soluble rather than from large insoluble HTTex1 
protein assemblies. 
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Finally, we also assessed whether HTTex1 seeds are detectable in R6/2Q212 
mouse brain extracts with transmission immunoelectron microscopy. Here, we 
focused on the pellet fraction P2 prepared by high speed centrifugation from the 
S1Med fraction (Figure 4A). It exhibits high HSA in FRASE assays but does not 
contain large, SDS-stable HTTex1 aggregates that are detectable by FRAs (Figures 
4B and 4C). We detected small, immunoreactive fibrillar HTTex1 assemblies with 
diameters of 10.2 ± 3.6 nm and lengths of 157.8 ± 64.1 nm in the P2 fraction, while 
such structures were not observed in the corresponding pellet fraction of control mice 
(Figure 4D). This suggests that very small, HTTex1 fibrils possess HSA in P2 
fractions. 
 
Establishment of an inducible HD Drosophila model for short-time expression 
of HTTex1 fragments in adult neurons  
To elucidate whether HTTex1 seeds with pathogenic polyQ tracts are disease-
relevant structures that cause dysfunction and toxicity in neurons, it is necessary to 
investigate their phenotypic consequences in vivo in the absence of large insoluble 
HTTex1 aggregates or the continuous overproduction of mutant disease protein. We 
hypothesized that the short-time production of small amounts of mutant HTTex1 
seeds in adult neurons might lead to increased mortality of transgenic HD flies, even 
though mutant HTTex1 expression is reduced to a minimum. 
To address this question, we generated two transgenic HD fly strains. Using 
the bacteriophage ΦC31 integration system, cDNAs encoding HTTex1 proteins with 
normal and pathogenic polyQ tracts (HTTex1Q17 and HTTex1Q97) were integrated 
into a predetermined intergenic locus (Bischof et al., 2007). The genotypes of the 
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newly created strains were confirmed by PCR using genomic DNA (Figure S5A). In 
order to investigate whether the two fly strains are comparable regarding their 
survival in the absence of HTTex1 expression, we generated w1118;HTTex1Q17 and 
w1118;HTTex1Q97 flies, which carry the transgenes but lack the GAL4 gene driver 
and therefore should not produce the HTTex1 proteins. Measuring the survival over 
time, we found that both fly strains showed a median life span of ~102 days (Figure 
S5B), indicating that the integration of transgenes does not influence fly survival. 
To induce HTTex1 protein expression in adult neurons we used the elav 
GeneSwitch (elavGS) system, an inducible pan-neuronal driver (Figures S5C). The 
elavGS driver (Osterwalder et al., 2001) was applied previously to create adult-onset 
Drosophila models for spinocerebellar ataxia 7 (Latouche et al., 2007) and 
Alzheimer’s disease (Sofola et al., 2010), suggesting that it may also be suitable to 
temporarily produce polyQ-containing HTTex1 proteins in neurons. Transgene 
expression in neurons of transgenic elavGS flies is induced when they are supplied 
with food containing the hormonal inducer RU486. Transgene expression can be 
switched off again, when flies are transferred back to food lacking the inducer 
(Rogers et al., 2012). 
We first performed proof-of-principle experiments to investigate whether 
RU486 treatment induces transgene expression in elavGS;HTTex1Q97 flies. We 
incubated adult flies for 1, 3, 6 and 12 days on food containing RU486 (400 µM) and 
quantified HTTex1Q97 transcript levels in fly heads by qPCR. We measured high 
amounts of HTTex1Q97 transcripts in brains of RU486 treated but not untreated flies 
(Figure S5D and S5E), confirming the functionality of the RU486-inducible 
expression system. Similar results were obtained when elavGS;HTTex1Q17 flies 
were analyzed (data not shown).  
	 18	
Finally, we assessed whether in RU486 treated elavGS HD flies mutant 
HTTex1 aggregates and HSA can be detected in adult fly brains. Starting at an age 
of 3 days, we treated elavGS;HTTex1Q97 and elavGS;HTTex1Q17 flies for 24 days 
with the expression activating hormone RU486. Head lysates were prepared and 
subsequently analyzed by FRA and FRASE assays. We observed the formation of 
large SDS-stable HTTex1Q97 aggregates by FRA in head extracts of RU486 treated 
elavGS;HTTex1Q97 flies. However, such structures were not detected in untreated 
elavGS;HTTex1Q97 flies (Figure S5F). Similarly, no SDS-stable aggregates were 
detectable in RU486 treated and untreated elavGS;HTTex1Q17 and 
w1118;HTTex1Q17/Q97 control flies (Figure S5F), indicating that large, SDS-stable 
fibrillar HTTex1Q97 structures are only formed in fly neurons, when the expression of 
the mutant protein is induced by hormone treatment. Strikingly, in head lysates of 
hormone treated elavGS;HTTex1Q97 flies besides SDS-stable HTTex1Q97 
aggregates (Figure S5F) also HSA was detectable with the FRASE assays (Figure 
S5G), indicating that seeding-competent fibrillar HTTex1 aggregates are formed in fly 
neurons. In contrast, HSA was undetectable in brains of untreated 
elavGS;HTTex1Q97 flies as well as in treated and untreated elavGS;HTTex1Q17 
flies and in w1118;HTTex1Q17/Q97 control flies of the same age (Figure S5G).  
 
Short-time expression of HTTex1Q97 in adult neurons decreases lifespan and 
locomotor activity of HD transgenic flies  
We first assessed whether HTTex1 transcripts decline when 
elavGS;HTTex1Q97 flies are placed back on food without the inducer. We observed 
that HTTex1Q97 transcripts indeed rapidly decrease in neurons of untreated flies 
(within ~24 h; Figures S6A and S6B), confirming previously published results that 
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transgene expression can be efficiently turned off in transgenic elavGS flies (Rogers 
et al., 2012). 
We next investigated whether both long- and short-time expression of 
HTTex1Q17 or HTTex1Q97 in adult neurons influences survival of HD transgenic 
flies. Starting at an age of 3 days, we treated elavGS;HTTex1Q17 and 
GS;HTTex1Q97 flies either continuously or only for a short time of 3 or 6 days with 
the expression activating hormone RU486 (Figure 5A); survival was measured over 
time by counting dead flies. We found that the lifespan of chronically RU486 treated 
elavGS;HTTex1Q97 flies was significantly reduced in comparison to untreated flies 
(Figure 5B and 5C). In strong contrast, chronic treatment with RU486 did not shorten 
the lifespan of elavGS;HTTex1Q17 flies, indicating that the neuronal expression of 
HTTex1Q97 but not of HTTex1Q17 promotes mortality. We calculated a median 
lifespan of ~30 and ~85 days for treated and untreated elavGS;HTTex1Q97 flies, 
respectively, indicating that chronic RU486 exposure shortens median lifespan by 
~65%. Interestingly, short-time RU486 treatment also dramatically shortened the 
lifespan of elavGS;HTTex1Q97 flies. We calculated median lifespans for 3- and 6-
day-treated flies of ~38 and ~33 days, respectively (Figure 5B and 5C), indicating 
that survival of both short- and long-time RU486 treated elavGS;HTTex1Q97 flies is 
similar. 
As a behavioral measure of neuronal dysfunction, locomotor activity was 
assessed in our inducible HD model using a negative geotaxis (climbing) assay that 
has been extensively applied to characterize fly models of neurodegenerative 
diseases (Latouche et al., 2007; Sofola et al., 2010). We observed that RU486-
treated, elavGS;HTTex1Q97 flies show a significant decline in climbing behavior in 
comparison to untreated controls (Figure 5D), confirming that both short and long-
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time expression of HTTex1Q97 in adult neurons induces dysfunction and 
neurotoxicity with severe phenotypic consequences. 
 
Formation of small, seeding-competent HTTex1Q97 structures in adult neurons 
correlates with reduced survival of HD transgenic flies 
 We first assessed whether reduced survival of long- and short-time RU486-
treated elavGS;HTTex1Q97 flies (Figure 5B and 5C) is associated with increased 
deposition of large, SDS-stable HTTex1 aggregates in neurons, which can be 
quantified by FRAs (Wanker et al., 1999). Head lysates were prepared from 
continuously and short-time (3 and 6 days) RU486-treated and untreated flies 
(Figure S6C) and subsequently analyzed by FRA using the anti-HTT antibody MW8 
(Ko et al., 2001). We found that the abundance of large, SDS-stable HTTex1Q97 
aggregates was much higher in heads of chronically RU486-treated 
elavGS;HTTex1Q97 flies than in heads of short-time-treated flies (Figure 5E), 
indicating that the formation of large, SDS-stable HTTex1Q97 aggregates in neurons 
cannot explain the observed mortality of HD transgenic flies, which is similar for 
short- and long-time RU486-treated flies (Figure 5C). A similar result was obtained 
when the formation of large HTTex1Q97 aggregates in fly heads was quantified by 
FRAs using the anti-HTT antibody MB5492 (Figure S6D). Together these 
experiments indicate that the accumulation of large, SDS-stable HTTex1Q97 
aggregates in neurons does not correlate with the observed mortality of short- and 
long-time RU486-treated elavGS;HTTex1Q97 flies (Figure 5B). 
 Next, we also investigated the formation mutant HTTex1 aggregates in brains 
of hormone treated and untreated elavGS;HTTex1Q97 flies using an 
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immunohistochemical method. We dissected whole brains of 27 day-old short and 
long-time treated elavGS;HTTex1Q97 flies (Figure S6C) and incubated them with 
the monoclonal anti-HTT antibody MAB5492. As a control, the brain sections were 
also immunoassayed with an anti-RBP (RIM-binding protein) antibody, which detects 
synapses in fly brains (LIT). As expected, we detected high amounts of HTTex1Q97 
aggregates (green puncta) in long-time and lower amounts in short-time (3 and 6 
days) hormone-treated HD flies (Figure S6E), confirming the results obtained with 
FRAs (Figure 5E). Interestingly, our immunohistochemical investigations also 
revealed that very low amounts HTTex1Q97 aggregates are detectable in 27 day-old 
non-induced elavGS;HTTex1Q97 flies (Figure S6E), indicating low levels of mutant 
HTTex1 protein are also expressed in the absence of hormone treatment. However, 
this low level expression of HTTex1Q97 was not sufficient to significantly shorten the 
lifespan of HD transgenic flies (Figure 5C).  
Finally, we used the FRASE assay to quantify HSA in head lysates prepared 
from long- and short-time RU486-treated elavGS;HTTex1Q97 flies to determine 
whether seeding activity better predicts the survival phenotype than the detection of 
large aggregates with FRAs (Figure 5E). Strikingly, we measured high HSA in head 
lysates of both short- and long-time RU486-treated flies (Figure 5F and 5G), 
demonstrating that the FRASE assay provides information that is fundamentally 
different from that obtained with FRA. As seeding activity in neurons of short-time 
treated flies cannot result from large fibrillar aggregates (Figure 5E and S6D), it must 
be due to smaller structures that are not retained by the filter membrane. In 
comparison to RU486-treated elavGS;HTTex1Q97 flies, HSA was undetectable in 
head lysates of elav;HTTex1Q17 control flies (Figure 5F).  
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In contrast to the FRA results (Figure 5E and S6D), HSA levels measured with 
the FRASE assay (Figure 5F and 5G) correlate significantly better with the increased 
mortality of RU486-treated elavGS;HTTex1Q97 flies (Figure 5H). Together, these 
experiments suggest that the formation of small seeding-competent HTTex1Q97 
structures is necessary and sufficient to trigger dysfunction and neurotoxicity in 
neurons of elavGS;HTTex1Q97 flies.  
 
Short-time expression of the molecular chaperone Hsp70 in adult neurons 
extends the lifespan of HD transgenic flies  
Previous studies have demonstrated that the human molecular chaperone 
Hsp70 (HSPA1L) can reduce polyQ-mediated dysfunction and neurodegeneration in 
Drosophila models (LIT, LIT), suggesting that it may also influence HSA and toxicity 
in neurons of adult HTTex1Q97 transgenic flies. To address this question, we 
generated elavGS;HSPA1L;HTTex1Q97 flies, which facilitate the short-time co-
production of both Hsp70 and HTTex1Q97 in adult neurons upon hormone treatment. 
We first assessed whether RU-486 treatment induces similar levels of HTTex1Q97 
transcripts in brains of elavGS;HSPA1L;HTTex1Q97 and elavGS;HTTex1Q97 HD 
control flies. We treated 3-day-old flies for 6 days with RU-486 (400 µM) and 
subsequently quantified mutant HTTex1 transcript levels in fly heads by qPCR. We 
confirmed that hormone treatment stimulates HTTex1Q97 expression in neurons 
(Figure S7A). Furthermore, we observed that in both strains HTTex1Q97 transcript 
levels are very similar, indicating that co-expression of HSPA1L does not significantly 
influence HTTex1 expression in elavGS;HSPA1L;HTTex1Q97 flies. 
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To confirm the expression of Hsp70 in elavGS;HSPA1L;HTTex1Q97 flies, we 
next also analyzed protein extracts from heads of hormone treated animals by SDS-
PAGE and immunoblotting. As expected, in head lysates prepared of hormone-
treated flies a relatively high concentration of Hsp70 protein was detectable (Figure 
S7B), confirming that transgene expression is induced in HD flies. Furthermore, we 
observed similar Hsp70 levels in brains of hormone-treated 
elavGS;HSPA1L;HTTex1Q97 and elavGS;HSPA1L flies (Figure S7B), indicating that 
HTTex1Q97 co-expression (Figure S7A) does not significantly influence Hsp70 
protein production in neurons of transgenic elavGS;HSPA1L;HTTex1Q97 flies. 
Finally, we assessed whether short-time expression of Hsp70 (for 6 days) in 
adult neurons of 3-day-old elavGS;HSPA1L;HTTex1Q97 HD flies is sufficient to alter 
their survival phenotype. In control experiments, the short-time expression of 
HTTex1Q97 alone in elavGS;HTTex1Q97 flies was also investigated. Strikingly, we 
found that RU-486 treated elavGS;HSPA1L;HTTex1Q97 flies have a median lifespan 
of ~39 days, while it was ~33 days for hormone-treated elavGS;HTTex1Q97 flies 
(Figure 6A-6C). This indicates that even short-time co-expression of Hsp70 in adult 
neurons is sufficient to improve the survival of elavGS;HSPA1L;HTTex1Q97 flies. As 
expected from our initial studies (Figure 5B) a median lifespan of ~85 days was 
observed for non-treated elavGS;HTTex1Q97 flies. 
 
Co-expression of Hsp70 decreases the abundance large HTTex1Q97 
aggregates and of HSA in neurons of HD transgenic flies 
 To examine whether short-time expression (6 days) of Hsp70 in adult neurons 
influences mutant HTTex1 aggregation, head lysates of 13-day-old RU-486-treated 
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elavGS;HSPA1L;HTTex1Q97 flies were analyzed by FRAs. We found that in 
comparison to hormone treated elavGS;HTTex1Q97 control flies, the abundance of 
large, SDS-stable HTTex1Q97 aggregates was significantly decreased in neurons of 
elavGS;HSPA1L;HTTex1Q97 flies (Figure 6D), supporting previous observations 
that high levels of Hsp70 proteins can decrease the formation of large HTTex1 
aggregates (LIT, LIT). Strikingly, in head lysates of RU-486-treated 
elavGS;HSPA1L;HTTex1Q97 flies in comparison to elavGS;HTTex1Q97 control flies 
HSA detected by FRASE assays was also significantly decreased (Figure 6E and 
6F), substantiating our hypotheses that seeding-competent HTTex1Q97 aggregates 
cause toxicity and dysfunction in fly neurons. 
 Finally, we addressed the question whether the molecular chaperone Hsp70 
associates with mutant HTTex1 aggregates in fly neurons. Immunohistochmical 
investigations of brain slices prepared from 9 day-old elavGS;HSPA1L;HTTex1Q97 
flies treated for 6 days with the hormone Ru-486 revealed co-localization of the 
molecular chaperone Hsp70 and HTTex1Q97 aggregates in HD brains (Figure 6G), 
supporting previous observations that Hsp70 directly interacts with mutant polyQ-
containing HTTex1 proteins and decreases their aggregation propensities (LIT, LIT).  
 
Depletion of Hsc70 increases both toxicity and Q35-YFP seeding activity in a 
C.elegans model 
 Our studies indicate that short-time overproduction of the molecular chaperone 
Hsp70 improves survival of elavGS;HSPA1L;HTTex1Q97 HD flies and decreases 
HSA in neurons (Figure 6C and 6F), suggesting that a decrease of chaperone 
expression might have the opposite effects on seeding and mHTT-induced toxicity in 
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model systems. To address this question, we performed RNAi knockdown 
experiments in transgenic worms that overproduce the aggregation-prone protein 
Q35-YFP in wall muscle cells. Previous studies have demonstrated that Q35-YFP 
aggregation in muscle cells leads to motor impairment and that this phenotype gets 
even more severe when the expression of the hsp-1 gene (encoding the molecular 
chaperone Hsc70) is knocked down by RNAi (Brehme et al., 2014; Nollen et al., 
2004). We treated Q35-YFP expressing worms with hsp-1 RNAi and assessed their 
movement at day 5 of adulthood.  We observed a significant reduction of motility in 
RNAi-treated in comparison to untreated worms (Figure S8A), confirming previously 
published results (Brehme et al., 2014). Furthermore, this phenotypic change was 
associated with a significant increase in Q35-YFP seeding activity in FRASE assays 
(Figure S8B and S8C), supporting our hypothesis that HSA is maker of dysfunction 
and toxicity in model systems.  
 
DISCUSSION 
There is increasing experimental evidence that self-propagating mutant HTT 
aggregates, or seeds, play an important role in the development of disease in HD 
model organisms (Babcock and Ganetzky, 2015; Brundin et al., 2010; Pecho-
Vrieseling et al., 2014). Whether they are indeed critical or even responsible for the 
appearance and progression of disease, however, is still unclear. To address this 
question, we developed a FRET-based biosensor (FRASE) assay that enables the 
sensitive quantification of mutant HTT seeding activity (HSA) in complex biosamples. 
With this assay in hand, we assessed the potential correlation between HSA in 
affected tissues and the appearance of disease phenotypes in HD transgenic mice 
(Figures 3). We detected robust HSA in crude brain extracts of mice weeks before 
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manifestation of disease (Figures 3E-3G). Furthermore, we observed an increase of 
mutant HSA in mouse brain extracts concomitantly with the appearance of 
symptoms, suggesting that it quantitatively tracks disease progression. Finally, 
comprehensive mechanistic studies with a newly established inducible Drosophila 
model of HD indicate that the formation of small, seeding-competent HTTex1Q97 
structures in adult neurons are necessary and sufficient to significantly shorten the 
lifespan of HD flies, supporting our hypothesis that mutant HTT seeding is a disease-
relevant process causing dysfunction and neurotoxicity. Taken together, these 
studies indicate that HSA is a valuable early disease marker that can predict severe 
downstream phenotypic changes in various HD models. 
The fluorescent dye Thioflavin T (ThT) is currently utilized in a large number of 
cell-free assays as a reporter molecule to monitor the seeding activity of 
amyloidogenic protein aggregates (Gupta et al., 2012; Salvadores et al., 2014). ThT 
exhibits enhanced fluorescence when it is bound to β-sheet-rich amyloid structures 
(LeVine, 1993). However, its binding to such structures is significantly decreased, 
when competing proteins are present in complex amyloid polymerization reactions 
(Biancalana and Koide, 2010; LeVine, 1993). Therefore, previously established ThT-
based seeding assays are relatively insensitive when complex biosamples such as 
brain homogenates are analyzed: For example, it was demonstrated that mutant HTT 
seeds need to be enriched from crude mouse brain homogenates in order to be 
successfully amplified with a ThT-based HTT seeding assay (Gupta et al., 2012).  
To overcome these limitations, we have established a FRET-based biosensor 
assay, which does not require ThT reporter molecules for the quantification of HSA in 
biosamples. Two fluorescently tagged aggregation-prone HTT exon-1 fusion proteins 
with 48 glutamines (Ex1Q48-CyPet/-YPet) are used as reporter molecules to monitor 
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seeding activity (Figure 1C). These proteins self-assemble into stable fibrillar co-
aggregates under both seeded and non-seeded conditions and yield FRET-based 
aggregation profiles from which HSA in biosamples is quantified (Figure 3A). This 
process is highly robust and affected by contaminating proteins in complex 
biosamples only to a very small extent. Therefore, the FRASE assay can be 
employed without the need for upstream purification of HTT seeds, which would 
complicate the protocol and decrease accuracy of quantification. Also, the method is 
highly sensitive and specific (Figure 2B-2E), indicating that it is a suitable tool for 
routine application in research and development. 
We observed high HSA in soluble fractions of transgenic HD mouse brain 
extracts (Figure 4B and 4C), suggesting that greater seeding activity is associated 
with smaller particles. However, inclusions with insoluble fibrillar HTTex1 aggregates 
(Bäuerlein et al., 2017) may also possess seeding activity. Further studies will be 
necessary to purify fibrillar HTTex1 structures of different sizes from mouse and fly 
brains and to compare their specific seeding activity (i.e., seeding activity per unit of 
protein). We assume that there is a continuum of mutant HTT species in disease 
brains that all have some seeding activity. However, similar to previously published 
results for infectious prion species (Silveira et al., 2005), we provide initial evidence 
that the specific activity may be higher for smaller mutant HTTex1 structures than for 
larger aggregates.  
Our results are in agreement with previous investigations indicating that small, 
fibrillar polyQ-containing HTT assemblies are detectable in the cytoplasm of cells 
besides large inclusions with fibrillar mHTT aggregates (Sahl et al., 2012; 
Sathasivam et al., 2010). They are also consistent with experimental studies 
demonstrating that proteotoxicity in mammalian cells is associated with small, 
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diffusible HTT oligomers rather than large inclusions (Arrasate et al., 2004; Kim et al., 
2016; Leitman et al., 2013; Taylor et al., 2003). However, our present study 
advances beyond the state-of-the-art. For the first time, we provide experimental 
evidence that seeding of HTTex1Q97 is associated with dysfunction and 
neurotoxicity in neurons of HD transgenic flies in the absence of detectable large, 
insoluble HTT aggregates (Figures 5 and 6). We suggest that small, seeding-
competent structures are formed which shorten the lifespan of HD flies through 
aberrant interaction with essential fly proteins, perturbing their normal physiological 
functions. Further mechanistic investigations, however, will be necessary to elucidate 
the critical downstream molecular changes that are induced by HTTex1Q97 seeding 
in neurons of HD transgenic flies.  
Together, our investigations indicate that mutant HTT seeds in brains of HD 
transgenic mice and flies are an early pathological manifestation of disease; they 
increase in their abundance with the development of disease phenotypes (Figure 
3E-3G). We suggest that HSA in mouse brain extracts is a biological marker of 
disease long before onset. Previous studies argue that the abundance of large 
insoluble HTT aggregates in brains of HD mice and patients is not predictive for the 
development of symptoms (Kuemmerle et al., 1999; Slow et al., 2005). However, 
neuronal inclusions with insoluble aggregates are commonly detected with 
immunohistological methods, which fail to identify small, seeding-competent HTT 
assemblies in disease brains. The application of the FRASE assay overcomes this 
important limitation associated with standard histology and is likely to yield new 
mechanistic insights into the progressive development of HD. 
We propose that in future drug trials with transgenic HD mice HSA could be 
utilized as an outcome marker to monitor the efficacy of therapeutic molecules in 
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vivo, before and independent of changes in phenotype. We detected robust HSA in 
the striatum of 2-month-old HdhQ150 transgenic mice (Figure 3G). Drug treatment 
could start before that point in time and animals could be assessed for HSA at any 
age after two months. Furthermore, we propose that the FRASE method can be 
applied as a drug screening assay to identify therapeutic molecules that directly 
target mutant HTT seeding in vitro. Because the assay can monitor mutant HSA in 
protein extracts from postmortem patient brain and transgenic animals (Figure 3D-
3G), it seems now feasible to investigate therapeutic candidate molecules in assays 
which contain disease-relevant seeds amplified from those extracts. 
Through the application of a FRET-based biosensor assay, we have 
demonstrated that HSA is a robust, early disease biomarker in HD transgenic mice. 
We propose that it also might be of high value for monitoring disease onset and 
progression in HD patients if HSA could be quantified in biosamples whose collection 
is technically and ethically possible, like cerebrospinal fluid, blood or muscle tissue. 
Through the quantification of HSA in patient samples, the optimal time point for the 
initiation of clinical trials could be determined and the efficacy of therapeutic 
interventions could be monitored. In this way, our findings may help to develop novel 
disease-modifying therapeutic strategies for HD and other polyQ diseases.  
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FIGURES LEGENDS 
Figure 1. Establishment of a FRET-based HTT aggregate seeding assay  
(A) Analysis of the aggregation propensity of proteolytically cleaved GST-Ex1Q48-
CyPet and -YPet fusion proteins. Both sensor proteins (3 µM) were individually 
incubated at 25 °C with PreScission protease (PSP); time-dependent formation of 
SDS-resistant aggregates was analyzed by FRA. A polyclonal anti-GFP antibody 
recognizing both tags (CyPet and YPet) was used for visualization of spontaneously 
formed aggregates.  
(B) Atomic force microscopy (AFM) analysis of spontaneously formed Ex1Q48-
CyPet, Ex1Q48-YPet and Ex1Q48 aggregates (3 µM) after 24 h. Scale bars: 1 µm; 
color gradient represents 0-20 nm height.  
(C) Schematic model of the spontaneous FRET-inducing Ex1Q48-CyPet/-YPet co-
aggregation reaction in cell-free assays. Initially, the N-terminal GST-tag keeps the 
fusion proteins in a soluble state and prevents spontaneous aggregation. After PSP-
mediated cleavage of the fusion proteins, Ex1Q48-CyPet and -YPet fragments are 
released and spontaneously co-aggregate over time. Co-aggregation is monitored by 
quantification of FRET, arising when fluorescent tags come into close proximity in 
ordered protein aggregates. 
(D) Investigation of spontaneous co-aggregation of sensor proteins by time-
dependent quantification of FRET. Various concentrations of the sensor proteins 
Ex1Q48-CyPet and -YPet (1:1 mixture) were incubated at 25 °C in the presence and 
absence of PSP. The initial FRET signal of ~6% is due to oligomerization of 
uncleaved fusion proteins under non-denaturating conditions. FRET efficiency is 
displayed as mean ± SD of technical triplicates. 
(E) Preformed, fibrillar Ex1Q48 aggregates (seeds) induce a concentration-
dependent acceleration of Ex1Q48-CyPet/-YPet (1.2 µM) polymerization in cell-free 
	 38	
assays. Co-aggregation of the fluorescence sensor proteins was monitored by 
quantification of FRET for 30 h; the resulting aggregation kinetics were curve fitted by 
non-linear regression. Indicated seed concentrations are equivalent to initially applied 
monomer concentrations. FRET efficiency is displayed as mean ± SD of technical 
triplicates. 
(F) Calculation of Δt50 values from aggregation profiles of seeded and unseeded 
reactions in E. HTT seeding activity (HSA) is detected in a concentration-dependent 
manner when preformed fibrillar Ex1Q48 aggregates are added to reactions. Δt50 is 
displayed as individual values (black ●) and mean ± SD of technical triplicates. 
 
Figure 2. FRASE assays facilitate the detection of preformed Ex1Q48 seeds 
with high specificity and sensitivity 
(A) Analysis of sonicated (1 min) and non-sonicated preformed fibrillar Ex1Q48 
aggregates by blue native (BN) PAGE and immunoblotting using the HD1 antibody.  
(B) Defining the detection limit of FRASE assays. A dilution series of sonicated 
Ex1Q48 seeds was systematically analyzed; seed concentrations were calculated 
using an average aggregate size of 1250 kDa. Ex1Q48-CyPet/-YPet (1.2 µM). Data 
are mean ± SEM (n = 5).  
(C) Calculation of Δt50 values from aggregation profiles in B results in a detection 
threshold for sonicated Ex1Q48 seeds of ~60 fM. The assay responds quantitatively 
to added seeds over more than four orders of magnitude (r2 = 0.988). Above a seed 
concentration of 556 fM the Z’ factor exceeds 0.5. Data are mean ± SEM (n = 5). 
(D) The FRASE assay specifically responds to preformed Ex1Q48 aggregates. 
Fibrillar aggregates prepared of amyloidogenic non-polyQ polypetides do not 
accelerate the co-aggregation of the reporter proteins Ex1Q48-CyPet/-YPet. Data are 
mean ± SD of triplicates. 
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(E) Analysis of preformed amyloidogenic α-synuclein (α-Syn), amyloid-β42 (Aβ), islet 
amyloid polypeptide (IAPP) and Tau (Tau40) protein aggregates by AFM. Scale bars: 
1 µm; color gradients represent the following heights: 0-10 nm (α-Syn), 0-5 nm (Aβ), 
0-30 nm (IAPP) and 0-10 nm (Tau40). 
 
Figure 3. Detection of mutant HTT seeding activity in brain extracts of HD 
patients and presymptomatic HD mice 
(A) Schematic representation of the FRASE assay workflow for detecting HSA in 
tissue homogenates. Tissues of interest are homogenized in detergent-free lysis 
buffer and cleared from cell debris by low-speed centrifugation. Fluorescent protein-
tagged Ex1Q48 sensor proteins are supplemented with defined amounts of prepared 
crude protein extracts. Subsequently, co-aggregation of the sensor proteins is 
monitored in 384-well plates by quantification of FRET. The presence of mutant HTT 
seeds in the analyzed biosamples shortens the lag phase of spontaneous Ex1Q48-
CyPet/-YPet co-aggregation. HSA (Δt50) in tissue samples is calculated from 
Ex1Q48-CyPet/-YPet aggregation profiles of seeded and non-seeded reactions. 
(B) FRASE analysis of brain homogenates prepared from an R6/2Q212 transgenic 
mouse and wild-type littermate control. The concentration of the sensor proteins 
GST-Ex1Q48-CyPet/-YPet was 3 µM. Data is presented as mean ± SD of technical 
triplicates. 
(C) Calculation of Δt50 values from aggregation profiles in B. Statistical significance 
was assessed by two-way ANOVA followed by Bonferroni’s multiple comparison post 
hoc test against the respective WT controls. Δt50 is displayed as individual values 
(black ●) and as mean ± SD of technical triplicates. Comparable results were 
obtained in two independent experiments.  
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(D) Quantification of HSA in brain homogenates prepared from cerebellum, caudate 
nucleus and cerebral cortex of HD patients and controls with FRASE assays. For 
clarity, the average Δt50 values obtained from six healthy control samples are 
depicted. Individual values of Δt50 (black ●) and mean ± SD of triplicates are 
displayed. 
(E) Quantification of mutant HSA in brain extracts prepared from R6/2Q212 
transgenic mice. Mice were sacrificed at the indicated age (3 mice per age); brain 
extracts were analyzed using the FRASE assay. Corresponding extracts from wild-
type (WT) littermate controls were analyzed for all ages; an average Δt50 value was 
depicted for clarity.  
(F) Analysis of sonicated brain extracts prepared from young R6/2Q212 transgenic 
mice using the FRASE assay. Results from corresponding littermates are shown as 
an average Δt50 value.  
(G) Investigation of brain extracts prepared from indicated brain regions of HdhQ150 
heterozygous knock-in mice. Corresponding extracts from 2-, 5- and 8-month-old WT 
mice were also analyzed and average Δt50 values are depicted for clarity. Data are 
mean ± SEM (n = 3). The concentration of the sensor proteins GST-Ex1Q48-CyPet/-
YPet in (D), (E), (F) and (G) is 1.2 µM. In (E), (F) and (G) HSA measured for each 
mouse is displayed as black ●. Bars are mean ± SEM. Statistical significance was 
assessed by One-Way ANOVA followed by Dunnett's multiple comparisons test. 
 
Figure 4. Small fibrillary HTT aggregates prepared from R6/2Q212 mouse brain 
are highly seeding competent 
(A) Scheme of the different centrifugation steps applied to prepare soluble and 
insoluble fractions from brain homogenates of R6/2Q212 transgenic mice.  
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(B) Quantification of HSA in soluble and insoluble fractions prepared by centrifugation 
from crude brain homogenates using FRASE assays. In all cases, data obtained for 
transgenic mice were normalized to age-matched wild-type control mice. Bars are 
mean ± SEM (n = 2). HSA measured for each mouse is displayed as black ●. 
(C) Analysis of soluble and insoluble fractions prepared by centrifugation from mouse 
brain homogenates using a denaturing FRA. 
(D) Analysis of the P2 fraction after high-speed centrifugation by immunoelectron 
microscopy. The P2 fraction was prepared from 9-week-old R6/2Q212 transgenic 
mice and age-matched wild-type (WT) controls. Fibrillar HTT aggregates were 
visualized with the anti-Agg53 HTT antibody and a gold-labeled secondary antibody. 
Scale bar corresponds to 100 nm. 
 
Figure 5. The short-term mHTT-expression-induced decrease in Drosophila 
lifespan correlates with HSA but not with aggregate load in general 
(A) Scheme of temporary hormone treatment. The black lines indicate time periods of 
hormone treatment (RU486 food); the grey lines indicate time periods without 
hormone treatment (normal food). Treatment started at day three post-eclosion. 
(B) Life span analysis of GS;HTTex1Q97 and GS;HTTex1Q17 flies expressing the 
respective transgene for 0d (OFF; nGS;HTTex1Q97 = 99, 96, 107; nGS;HTTex1Q17 = 107, 
102, 100), 3d (3d-ON/OFF; nGS;HTTex1Q97 = 107, 108, 107; nGS;HTTex1Q17 = 109, 96, 97), 
6d (6d-ON/OFF; nGS;HTTex1Q97 = 108, 105, 94; nGS;HTTex1Q17 = 110, 97, 100) or 
permanently (ON; nGS;HTTex1Q97 = 102, 98, 106; nGS;HTTex1Q17 = 100, 109, 101). Life 
span is plotted as the percentage of surviving flies of three biological replicates. 
(C) Median life span calculated from survival curves in B. Average survival of each 
experiment (n = ~ 100 flies) is presented as black ●. Bars are mean ± SEM from 
three independent replicates; Statistical significance was assessed by One-way 
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ANOVA Dunnett’s post-hoc test; data were compared to GS;HTTex1Q97OFF 
transgenic flies [statistically significant differences are indicated by asterisks (*)] or to 
GS;HTTex1Q97ON flies [statistically significant differences are indicated by hashtags 
(#)]; ns, not statistically significant; */# p <0.05; **/## p <0.01; ***/### p <0.001. 
(D) Analysis of motor performance of GS;HTTex1Q97 flies expressing the respective 
transgene for 0d (OFF), 3d (3d-ON/OFF), 6d (6d-ON/OFF) or permanently (ON). 
Results are presented as mean of three independent replicates each starting with 
100 flies per condition. 
(E) Quantification of HTT aggregate load in fly heads by FRAs immunodetected with 
the MW8 antibody. Representative images for each condition are shown below the 
bar graph. Data are displayed as mean ± SEM; Individual measurements are 
presented as black ●; One-way ANOVA Dunnett’s post hoc test. 
(F) FRASE analysis of head lysates from flies analyzed in E. Values are plotted as 
means ± SEM of three biological replicates each performed in triplicates. 
(G) HSA calculated from aggregation kinetics in F. Results are displayed as mean ± 
SEM; Individual measurements are presented as black ●; One-way ANOVA 
Dunnett’s post hoc test compared to GS;HTTex1Q97OFF flies.  
(H) Pearson correlation analysis shows a significant linear relationship between 
Drosophila lifespan and HSA assessed by FRASE assays (p = 0.020), whereas 
Drosophila lifespan does not correlate with the aggregate load detected by FRAs [p = 
0.368 (FRA,MAB5492), p = 0.411 (FRA, MW8)]. All data are presented as mean ± 
SEM of the three individual experiments. 
 
Figure 6. Co-expression	of	 the	human	molecular	 chaperone	Hsp70	 reduces	HSA	
and	HTTex1Q97	induced	toxicity	in	HD	transgenic	flies 
	 43	
(A) Scheme of temporary hormone treatment. The orange/green lines indicate time 
periods of hormone treatment (RU486 food); the grey lines indicate time periods 
without hormone treatment (normal food). Treatment started at day three post-
eclosion. 
(B) Life span analysis of GS;HTTex1Q97 and GS;HSPA1L;HTTex1Q97 flies 
expressing the respective transgenes for 6d (6d-ON/OFF; nGS;HTTex1Q97 = 108, 105, 
94; nGS;HSPA1L;HTTex1Q97 = 103, 82, 83). As comparison the survival curve of untreated 
GS;HTTex1Q97 (OFF) from 5B is shown. Life span is plotted as the percentage of 
surviving flies of three biological. 
(C) Median life span calculated from survival curves in B. Average survival of 
individual experiments (n = ~ 100 flies) is presented as black ●. Bars are mean ± 
SEM from three independent replicates; Statistical significance was assessed by 
unpaired t test. 
(D) Quantification of HTT aggregate load in fly heads by FRAs immunodetected with 
the MW8 antibody. Representative images for each condition are shown below the 
bar graph. Data are displayed as mean ± SEM; Individual measurements are 
presented as black ●; Statistical significance was assessed by unpaired t test. 
(E) FRASE analysis of fly head lysates. Values are plotted as mean ± SEM of three 
biological replicates each performed in triplicates. 
(F) HSA calculated from aggregation kinetics in E. Results are displayed as mean ± 
SEM; Individual measurements are presented as black ●; Statistical significance was 
assessed by unpaired t test. 
(G) Representative confocal images of the right central brain regions 
GS;HSPA1L;HTTex1Q97 treated for 6 days with RU486 immunostained for HTT 
(Mab5492, green) and Hsp70 (anti-HSP70/HSP72, red). White arrows indicate co-
localization of HSPA1L with HTT aggregates. Grey arrow indicates areas in the 
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brain where Hsp70 is not associated with HTT aggregates. Scale bars: 20 µm. 
 
Figure S1 related to Figure 1: Characterization of HTTex1 sensor proteins  
(A) Schematic representation of the applied GST-tagged HTTex1 fusion proteins with 
pathogenic and non-pathogenic polyQ tracts. P, proline-rich regions. 
(B) The recombinant GST-Ex1Q48-CyPet and -YPet fusion proteins were affinity 
purified using glutathione-coated sepharose beads. Purity was assessed by SDS-
PAGE and subsequent Coomassie blue staining.  
(C) Investigation of the PreScission protease (PSP)-mediated cleavage of the GST 
tag from the GST-Ex1Q48-CyPet and -YPet fusion proteins. 3 µM of GST fusion 
proteins were incubated in the presence or absence of the protease. Aliquots were 
taken at the indicated time points; cleavage was confirmed by SDS-PAGE and 
immunoblotting with a polyclonal anti-GFP antibody.  
(D) AFM analysis of the co-aggregated sensor proteins Ex1Q48-CyPet/-YPet (3 µM). 
Scale bars: 1 µm; color gradient represents 0-20 nm height.  
(E) Preformed, fibrillar Ex1Q48 aggregates (seeds) induce acceleration of Ex1Q48-
CyPet/-YPet polymerization but do not induce aggregation of Ex1Q23-CyPet/-YPet. 
Seeds were produced by incubating GST-Ex1Q48 fusion protein with PSP for 24 h at 
25°C. Indicated seed concentrations are equivalent to initially applied monomer 
concentrations. Co-aggregation of the fluorescence sensor proteins (1.2 µM) was 
monitored by quantification of FRET for 30 h; the resulting aggregation kinetics were 
curve fitted by non-linear regression. FRET efficiency is plotted as means ± SD of 
three technical replicates. 
(F) Ex1Q48-CyPet/-YPet (3µM) sensor protein co-aggregation was accelerated by 
the addition of preformed fibrillary Ex1Q48 seeds. Ex1Q23 was prepared under 
identical condition (no fibrillar aggregates observed; data not shown) but did not 
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accelerate the co-aggregation of Ex1Q48-CyPet/-YPet sensor proteins. Likewise, the 
co-aggregation of sensor proteins was not influenced by the addition of uncleaved 
GST-Ex1Q48 or GST-Ex1Q23, respectively. Co-aggregation of the fluorescence 
sensor proteins was monitored by quantification of FRET for 12 h; the resulting 
aggregation kinetics were curve fitted by non-linear regression. Indicated seed 
concentrations are equivalent to initially applied monomer concentrations. Data is 
shown as means ± SD of three technical replicates. 
 
Figure S2 related to Figure 2. Both small and large fibrillar Ex1Q48 aggregates 
exhibit HTT seeding activity in FRASE assays   
(A) Sonication of preformed, fibrillar Ex1Q48 aggregates reveals protein fractions 
with high HSA in FRASE assays. Fibrillar Ex1Q48 aggregates were produced by 
incubating GST-Ex1Q48 fusion protein (2 µM) for 24 h at 25°C. 1 nM preformed 
Ex1Q48 aggregates were added to reactions (Ex1Q48-CyPet/-YPet sensor protein 
concentration = 1.2 µM). The added seed concentration is equivalent to the initially 
applied monomer concentration. Data is shown as means ± SD of three technical 
replicates. 
(B) Calculated Δt50 values from Ex1Q48-CyPet/-YPet aggregation profiles in A. Δt50 is 
displayed as individual values (black ●) and mean ± SD of technical triplicates. 
(C) Analysis of sonicated and non-sonicated Ex1Q48 seeds by denaturing filter 
retardation (FRA, left panel) and dot blot (DB, right panel) assays. Fragmentation of 
large fibrillar Ex1Q48 aggregates by sonication prevents their detection in FRAs. 
(D) Preformed Ex1Q48 fibrils were sonicated for the indicated times and visualized 
by AFM. Sonication reduces the size of preformed fibrillar Ex1Q48 aggregates. Scale 
bar: 1 µm; color gradient represents 0-20 nm height. 
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Figure S3 related to Figure 3. Detection of mutant HTT seeding activity in brain 
extracts of various HD mouse models 
(A) Mouse brain homogenates (7.5 µg) prepared from R6/2Q212 and WT were 
added to Ex1Q48-CyPet/-YPet or Ex1Q23-CyPet/-YPet sensor proteins. R6/2Q212 
brain homogenates accelerate Ex1Q48-CyPet/-YPet polymerization but do not 
induce co-aggregation of Ex1Q23-CyPet/-YPet proteins. Co-aggregation of the 
fluorescence sensor proteins (1.2µM) was monitored by quantification of FRET for 30 
h and displayed as mean ± SD of technical triplicates; the resulting aggregation 
kinetics were curve fitted by non-linear regression. 
(B) Analysis of brain extracts prepared from R6/2Q51 transgenic mice and controls 
using FRASE assays (1.2 µM Ex1Q48-CyPet/-YPet). HSA measured for each mouse 
is displayed as black ●. Bars are mean ± SEM. Statistical significance was assessed 
by One-Way ANOVA followed by Dunnett's multiple comparisons test (n = 2).  
(C) Analysis of body weight of FVB/N mice expressing the proteins HTT853Q18 or 
HTT853Q79 for 8 weeks. Body weight of individual mice is displayed as black ●. Bars 
are mean ± SEM. Statistical significance was assessed by One-Way ANOVA 
followed by Dunnett's multiple comparisons test (n = 3). 
(D) Quantification of HSA in hypothalamic brain homogenates of FVB/N mice 
expressing the proteins HTT853Q18 or HTT853Q79. The concentration of sensor 
proteins was 3 µM. Data are mean ± SEM (n = 3). Individual measurements are 
displayed as black ●. Statistical significance was assessed by One-Way ANOVA 
followed by Dunnett's multiple comparisons test. 
(E) Brain homogenates prepared from caudate nucleus of HD patients and from 
temporal cortex of AD patients were analyzed by FRASE assays and compared to 
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corresponding brain tissue of control individual. HSA values are plotted individually 
(black ●) and  as mean ± SEM (n = 3); caudate tissue from HD patients (Grade 4, 
CAG repeat length: 52.3 ± 1.2, Age 42.3 ± 2.1), caudate tissue from controls (Age 
60.3 ± 1.2), cortical tissue from AD patients (Braak 6, Age 73.3 ± 4.6), cortical tissue 
from controls (Braak 0, Age 66.3 ± 7). Statistical significance was assessed by 
unpaired t test. 
 
Figure S4 related to Figure 3. Immunodepletion of HTT aggregates from mouse 
brain homogenates decreases HSA in FRASE assays  
(A) Immunodepletion of mutant HTT aggregates from R6/2Q212 mouse brain 
homogenates decreases their seeding activity in FRASE assays. Brain homogenates 
prepared from transgenic mice and littermate controls (12 weeks) were incubated 
with MW8 antibody-coated protein G beads; supernatant (post-IP) and input samples 
were applied to FRASE analysis using 3 µM of sensor proteins. FRET efficiency is 
plotted as mean ± SD of technical triplicates. 
(B) Same procedure as in A but with an IgG isotype control antibody.  
(C and D) Immunoblots of samples analyzed in A and B. HTT aggregates appear as 
a smear at the upper edge of the blot (red rectangles). Input, brain extract before 
immunodepletion; Sup, supernatant after immunodepletion; Beads, antibody-coated 
protein G beads after immunodepletion. HTT aggregates are depleted from mouse 
brain homogenates with the anti-HTT antibody MW8 but not with an IgG isotype 
control antibody. 
 
Figure S5 related to Figure 5. Temporal regulation of HTTex1Q97 transgene 
expression in newly generated Drosophila models of HD  
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(A) Confirmation of strain identity of HTTex1Q17 and HTTex1Q97 flies by PCR-
based genotyping. Expected sizes of PCR products: 526 bp (HTTex1Q17) and 766 
bp (HTTex1Q97). 
(B) Life span analysis of w1118;HTTex1Q97 and w1118;HTTex1Q17 flies 
(nw1118;HTTex1Q17 = 92, 176, 98; nw1118;HTTex1Q17 = 88, 148, 93). Life span is plotted as 
the percentage of surviving flies of three biological replicates. 
(C) Schematic illustration of The GAL4 / UAS and the Gene-Switch expression 
system. The yeast transcription activator GAL4 binds to the UAS sequence and 
activates the transcription of the transgene (TG) cloned downstream of the UAS. The 
Gene-Switch system is based on a of GAL4-progesterone receptor fusion protein 
which is not transcriptionally active until induced by steroids (RU486). This allows 
temporary regulation of transgene expression.  
(D) Schematic illustration of the RU486 treatment used to induce HTTex1Q97 
expression. Grey lines, no treatment; black lines, RU486 treatment.  
(E) qPCR analysis of induction of HTTex1Q97 transcription upon treatment with the 
inducer hormone RU486. The rp49 gene was used as reference gene. Results are 
depicted individually (black ●) and as mean ± SEM of three biological replicates; 
Statistical significance was assessed by One-way ANOVA Dunnett’s post-hoc test. 
(F) Analysis of HTT aggregate load in fly heads by FRAs immunodetected with the 
MW8 antibody. Two biological replicates are depicted per condition. 
(G) FRASE analysis of head lysates from flies analyzed in F. Values are plotted as 
means ± SEM of three biological replicates each performed in triplicates. 
 
Figure S6 related to Figure 5. Detection of HTT aggregates in Drosophila HD 
models 
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(A) Illustration of hormone treatment utilized to assess the dynamics of HTTex1Q97 
transcriptional repression upon hormone removal. Grey lines indicate time periods 
without RU486 treatment and black lines indicate time periods of exposure to RU486.  
(B) Relative mRNA levels assessed by qPCR show transcriptional repression of 
HTTex1Q97 upon removal of RU486. Values are depicted as mean ± SEM of three 
biological replicates; individual measurements (black ●); significance assessment 
with One-way ANOVA Dunnett’s post-hoc test. 
(C) Treatment scheme for the preparation of Drosophila samples for FRA and 
FRASE analyses. 
(D) Analysis of HTT aggregate load in fly head lysates by FRAs (75 µg protein) using 
the MAB5492 antibody. Data is displayed as mean ± SEM of three biological 
replicates; individual measurements (black ●); Statistical significance was assessed 
by One-way ANOVA Dunnett’s post-hoc test. 
(E) Representative confocal images of elavGS;HTTex1Q97 whole fly brains 
(hormone treatment as in C). The RBP staining is shown in magenta and the 
MAB5492 staining in green (Scale bars: 200 µm). Magnifications are shown below 
(Scale bars: 20 µm). 
 
 
Figure S7 related to Figure 6. Analysis of HTTex1Q97 and Hsp70 expression in 
elavGS;HTTex1Q97 and elavGS;HSPA1L;HTTex1Q97 flies 
(A) Relative mRNA levels assessed by qPCR show similar expression of HTTex1Q97 
in elavGS;HTTex1Q97 and elavGS;HSPA1L;HTTex1Q97. Bars are mean ± SEM of 
three biological replicates and individual measurements are displayed as black ●; 
significance assessment with unpaired t test. 
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(B) Comparison of HSPA1L protein levels in elavGS;HSPA1L;HTTex1Q97 and  
elavGS;HSPA1L flies untreated and treatment with ru-486. Protein extracts prepared 
from fly heads were analyzed in SDS-PAGE and immunoblotting (20 µg of total 
protein). 
 
Figure S8 related to Figure 6. Increased Q35-YFP seeding activity is associated 
with impairment of motility in transgenic worms  
(A) Motility phenotype (% motility) of RNAi-treated and untreated Q35-YFP 
expressing transgenic worms at day 5 of adulthood. In all cases, data were 
normalized to age-matched control worms. Data are mean ± SEM (n=20). 
Significance assessment with unpaired t test. 
(D) FRASE analysis of Q35-YFP seeding activity in RNAi-treated and untreated 
worms at day 5 of adulthood. FRET efficiency is displayed as mean ± SD. 
(E) Quantification of results shown in D. HSA values are plotted individually (black ●) 
and  as mean ± SD. 
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STAR * METHODS 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit polyclonal anti-GFP Abcam Cat#: ab290 
Rabbit polyclonal anti-HTT (HD1) Own production Scherzinger et al., 1999 
Mouse monoclonal anti-HTT (clone MW8) DSHB Cat#: MW8 
Rabbit polyclonal anti-Agg53 This paper N/A 
Goat polyclonal anti-HTT (N18) Santa Cruz Cat#: sc-8767 
Mouse monoclonal anti-HTT (clone 2B4) Merck Millipore Cat#: Mab5492 
Rabbit polyclonal anti-HSP70/HSP72 Enzo Life Science Cat#: ADI-SPA-812-D 
   
Bacterial and Virus Strains  
BL21-CodonPlus(DE3)-RP Integrated Science Cat#:	230255 
   
Biological Samples   
Post mortem brain tissues from human HD and 
AD patients and unaffected control individuals 
Newcastle Brain 
Tissue Resource  
   
Chemicals, Peptides, and Recombinant Proteins 
GST-HTTex1Q23 This paper N/A 
GST-HTTex1Q48 Wagner et al., 2018 N/A 
GST-HTTex1Q23-CyPet This paper N/A 
GST-HTTex1Q23-YPet This paper N/A 
GST-HTTex1Q48-CyPet Wagner et al., 2018 N/A 
GST-HTTex1Q48-YPet Wagner et al., 2018 N/A 
αSyn Theillet et al., 2016 N/A 
Tau40 InVivo BioTech Services N/A 
Mifepristone ru-486 Sigma Cat#: M8046-1G 
M-MLV Reverse Transcriptase Thermo Scientific Cat#: 28025013 
   
Critical Commercial Assays 
Pierce™ BCA Protein Assay Kit Thermo Scientific Cat#: 23225 
DNeasy® Blood & Tissue Kit Qiagen Cat#: 69504 
TRIzol™ Reagent Invitrogen Cat#: 15596026 
SYBR Green PCR Master Mix Thermo Scientific Cat#: 4309155 
   
Deposited Data 
   
Experimental Models: Cell Lines 
   
Experimental Models: Organisms/Strains 
Mouse: R6/2Q210 Mangiarini et al., 1996 N/A 
Mouse: CBA x C57Bl/6 Harlan Olac, Bicester, UK B6CBAF1/OlaHsd 
Mouse: HdhQ150 Lin et al., 2001 N/A 
Mouse: R6/2Q51 Larson et al., 2015 N/A 
Mouse: FVB/N   
Fly: Elavc115-GAL4 Lin et al., 1994 N/A 
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Fly: GSelav-GAL4 
Bloomington 
Drosophila Stock 
Center 
Bloomington Stock 43642 
Fly: HTTex1Q17 This paper N/A 
Fly: HTTex1Q97 This paper N/A 
Fly: HSPA1L Warrick et al., 1999 N/A 
   
Oligonucleotides 
HTTex1Q48 no Stop forward primer: 
5’-gacgacgaattcatggcgaccctg-3’ This paper N/A 
HTTex1Q48 no Stop reverse primer: 
5’- gacgacctcgagtggtcggtgcagcgg-3’ This paper N/A 
CyPet forward primer: 
5’-acgacctcgagggtggcggtggcggtatgtctaaag 
gtgaagaattattcgg-3’ 
This paper N/A 
CyPet reverse primer: 
5’- gacgacgcggccgcttatttgtacaattcatccatacc 
atg-3’ 
This paper N/A 
YPet forward primer: 
5’-gacgacctcgagggtggcggtggcggtatgtctaaa 
ggtgaagaattattcactgg-3’ 
This paper N/A 
YPet reverse primer: 
5’- gacgacgcggccgcttatttgtacaattcattcataccc 
tcg-3’ 
This paper N/A 
HTTex1Q23 no Stop forward primer: 
5’-gacgacgaattcatggcgaccctg-3’ This paper N/A 
HTTex1Q23 no Stop reverse primer: 
5’-gacgacgcggccgcctcgagtggtcggtg cagcgg-3’ This paper N/A 
HTTex1Q23 forward primer: 
5’-gacgacgaattcatggcgaccctg -3’ This paper N/A 
HTTex1Q23 reverse primer: 
5’-gacgacgcggccgcctcgagttatggtcggtgcagcgg-3’ This paper N/A 
Drosophila genotyping forward primer: 
5’-aaccccgtaaatcaactgc- 3’ This paper N/A 
Drosophila genotyping reverse primer: 
5’-atctctgtaggtagtttgtc-3’ This paper N/A 
HTTqPCR forward primer: 
5′-gacctggaaaagctgatga-3′ This paper N/A 
HTTqPCR reverse primer: 
5′-tcatggtcggtgcagcggct-3′ This paper N/A 
rp49qPCR forward primer: 
5′-tacaggcccaagatcgtgaa-3′ This paper N/A 
rp49qPCR reverse primer: 
5′-acgttgtgcaccaggaactt-3′ This paper N/A 
   
Recombinant DNA 
pBAD33-CyPet-His Addgene Addgene plasmid #14030 
pBAD33-YPet-His Addgene Addgene plasmid #14031 
   
Software and Algorithms 
AIDA	Image	Analyzer	v.3.21A AIDA N/A 
GraphPad	Prism GraphPad	software N/A 
JPK SPM software JPK	Instruments N/A 
   
Other 
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CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for reagents may be directed to, and will be fulfilled 
by the corresponding author Erich E. Wanker (ewanker@mdc-berlin.de). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
HD mouse models 
Hemizygous R6/2Q212 mice (Mangiarini et al., 1996) were bred by backcrossing 
R6/2Q212 males to (CBA x C57Bl/6) F1 females (B6CBAF1/OlaHsd, Harlan Olac, 
Bicester, UK). HdhQ150 heterozygous knock-in mice (Lin et al., 2001; Woodman et 
al., 2007) on a (CBA x C57Bl/6) F1 background were generated by intercrossing 
HdhQ150 heterozygous CBA/Ca and C57BL/6J congenic lines (inbred lines from 
Harlan Olac, Bicester, UK). All animals were subject to a 12 h light/dark cycle with 
unlimited access to drinking water and breeding chow (Special Diet Services, 
Witham, UK). Housing conditions and environmental enrichment were described 
previously (Hockly et al., 2003). R6/2 mice were always housed with wild-type mice. 
The CAG repeat size of the R6/2Q212 mice used in this study was 212 ± 5.27 (s.d.) 
and that of the HdhQ150 heterozygotes was 160 ± 2.86 (s.d.). Hemizygous R6/2Q51 
mice were derived from R6/2 parent lines by selective breeding (Larson et al., 2015) 
and bred by backcrossing R6/2Q51 males to (CBA x C57Bl/6) F1 females (Charles 
Rivers, UK). R6/2Q51 mice were maintained and bred as described previously 
(Larson et al., 2015). Female mice from the FVB/N strain were injected at eight to ten 
weeks of age with recombinant adeno-associated viral (AAV) vectors of serotype 5 
encoding the first 853 amino acids of either the WT form of HTT with 18Q (HTT853-
18Q) or the mutant form of the protein with 79Q (HTT853-79Q) (Baldo et al., 2013). 
All mice were housed in groups at a 12 h light/dark cycle. At eight weeks post-
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injection, FVB/N mice were sacrificed. Overall, mice were sacrificed at different ages 
from 1 day up to two years. Tissues were strictly stored at -80 °C until use. 
 All animal work with R6/2Q212 and HdhQ150mice was approved by the King’s 
College London Ethical Review panel and performed under a Home Office project 
license in accordance with the United Kingdom 1986 Animals (Scientific procedures) 
Act. All animal work with R6/2Q51 mice was approved by the University of 
Cambridge Ethical Review panel and performed under a Home Office project license 
in accordance with the United Kingdom 1986 Animals (Scientific procedures) Act. All 
experimental procedures with FVB/N mice were approved by the Regional Ethical 
Committee in Lund, Sweden. 
 
Human brain tissue 
Post mortem brain tissues from human HD and AD patients and unaffected control 
individuals (both male and female) were obtained from the Newcastle Brain Tissue 
Resource (NBTR, Newcastle University, UK). Experiments were performed in 
accordance with the approval of the joint Ethics Committee of Newcastle and North 
Tyneside Health Authority and following NBTR brain banking procedures. Tissues 
were collected at 34.5 ± 21.0 h post-mortem from HD patients and controls with an 
average age of 57.8 ± 10.7 years.   
 
Generation and maintenance of Drosophila strains 
ElavGS-GAL4, Elav-GAL4 and HSPA1L lines were obtained from the Bloomington 
Drosophila Stock Center. Transgenic flies were generated through cloning of cDNAs 
encoding HTTex1Q17 and HTTex1Q97 into pUAST-attB-rfA (provided by Prof. 
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Sigrist, Freie Universität, Berlin) and subsequent site-directed insertion on the third 
chromosome (68E) using the PhiC31 integrase [Rainbow Transgenic Flies Inc. 
(Camarillo, CA, USA)]. All Drosophila strains were cultured on standard medium at 
25°C and 65% humidity with a twelve-hour light-dark cycle. Expression of transgenes 
was induced by culturing flies on standard medium containing 400 µM RU486. 
 
C. elegans strains and maintenance 
C. elegans Q35 AM140 (rmIs132 (unc-54p::Q35::YFP)) were grown on NGM plates 
seeded with the E. coli OP50 strain at 20 °C. Nematodes were transferred to fresh 
wells or plates every day in the course of the experiment to separate them from their 
progeny. 
 
METHOD DETAILS 
Cloning of expression vectors 
For the construction of plasmids encoding CyPet- and YPet-tagged HTTEx1Q48 
fusion proteins, the coding sequence of HTTEx1Q48 was PCR-amplified from pGEX-
6P1-HTTEx1Q48 using the primers 5’-gacgacgaattcatggcgaccctg-3’ and 5’- 
gacgacctcgagtggtcggtgcagcgg-3’. The resulting PCR product was digested with the 
restriction enzymes EcoRI and NotI. Additionally, CyPet cDNA was PCR amplified 
from pBAD33-CyPet-His (Addgene plasmid #14030) (Nguyen and Daugherty, 2005) 
with the primers 5’-acgacctcgagggtggcggtggcggtatgtctaaaggtgaagaattattcgg-3’ and 
5’- gacgacgcggccgcttatttgtacaattcatccataccatg-3’. YPet cDNA was amplified from 
pBAD33-YPet-His (Addgene plasmid #14031) (Nguyen and Daugherty, 2005) with 
the primers 5’-gacgacctcgagggtggcggtggcggtatgtctaaaggtgaagaattattcactgg-3’ and 
	 56	
5’- gacgacgcggccgcttatttgtacaattcattcataccctcg-3’. The resulting PCR fragments were 
cloned into the plasmids pGEX-6P1 using the EcoRI/XhoI/NotI restriction sites to 
obtain plasmids pGEX-6P1-HTTEx1Q48-CyPet and -YPet, respectively. To generate 
the plasmids encoding GST-Ex1Q23-CyPet and -YPet or GST-Ex1Q23 the coding 
sequence of HTTEx1Q23 was PCR-amplified from pDONR221-HTTEx1Q23 using 
the primers 5’-gacgacgaattcatggcgaccctg-3’ and 5’-gacgacgcggccgcctcgagtggtcggtg 
cagcgg-3’ (GST-Ex1Q23-CyPet and -YPet) or 5’-gacgacgaattcatggcgaccctg -3’ and 
5’-gacgacgcggccgcctcgagttatggtcggtgcagcgg-3’. The resulting PCR products were 
digested using EcoRI and XhoI endonucleases and cloned into the plasmids pGEX-
6P1-HTTEx1Q48-CyPet, -YPet or pGEX-6P1-HTTEx1Q48 after excision of 
HTTEx1Q48 fragments by EcoRI/XhoI endonucleases.  
 
Recombinant protein expression 
The proteins GST-Ex1Q23, -Ex1Q48, -Ex1Q23-CyPet, -Ex1Q23-YPet, -Ex1Q48-
CyPet and -Ex1Q48-YPet were produced in E. coli BL21-CodonPlus-RP and affinity-
purified on glutathione-sepharose beads. Purified proteins were dialyzed over night 
at 4 °C against 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA and 5% glycerol, 
snap-frozen in liquid N2 and stored at -80 °C. Protein concentrations were determined 
with a NanoDrop spectrophotometer. Prior to use, protein solutions were ultra-
centrifuged at 190,000 x g for 40 min to remove aggregated material. α-Synuclein 
(αSyn) was produced in E. coli BL21 (DE3) and monomeric αSyn was purified as 
described elsewhere (Theillet et al., 2016). Expression of Tau40 protein was 
performed in E. coli BL21 using a 50 l bioreactor. After cell disruption using a French 
press, Tau40 protein was purified via cation exchange chromatography and gel 
	 57	
filtration. Expression and purification of Tau were performed by InVivo BioTech 
Services (Hennigsdorf, Germany) using proprietary company protocols. 
 
Preparation of in vitro seeds 
Spontaneous Ex1Q48 aggregation was initiated by addition of 14 U PreScission 
protease (GE Healthcare) per nmol purified GST-Ex1Q48 fusion protein (2 µM). The 
aggregation reaction was performed in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM 
EDTA and 1 mM DTT at 25 °C and constant agitation (450 rpm) for 24 h. Ex1Q23 
protein for seeding experiments was prepared from GST-Ex1Q23 fusion protein 
using the same protocol. Synthetic human IAPP was aggregated as described 
previously (Gao et al., 2015). Lyophilized αSyn was dissolved in PBS at 500 µM and 
centrifuged (4 °C, 265.000 x g) after a 5 min sonication step to remove aggregated 
material. The supernatant was incubated for 7 d at 37 °C under constant shaking in 
the presence of a single glass bead. Tau40 was aggregated for 6 d at 37 °C under 
constant shaking in 100 mM sodium acetate, pH 7.4, and 1 mM DTT in the presence 
of heparin. Synthetic human Aβ1-42 was dissolved in 100 mM NaOH and diluted to 
200 µM in low salt buffer (10 mM K3PO4, pH 7.4, 10 mM NaCl). Aggregation was 
performed for 6 h at 37 °C under constant agitation.     
 
Atomic force microscopy 
Aliquots of 15 µl aggregation reactions (24 h) were spotted onto freshly cleaved mica 
glued to a microscope slide. After incubation for 30 min to allow adsorption, samples 
were rinsed 4 times with 40 µl distilled water and dried over night at RT. Samples 
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were imaged with a digital multimode Nanowizard II (JPK, Germany) atomic force 
microscope operating in intermittent-contact mode.   
 
Filter retardation assays  
FRAs were essentially performed as described previously (Wanker et al., 1999). 
Briefly, equal volumes of 500 ng of Ex1Q48 aggregates and 4% SDS solution with 
100 mM DTT were mixed and boiled at 95 °C for 5 min. By applying vacuum, 
samples were filtered through a cellulose acetate membrane with 0.2 µm pores 
(Schleicher and Schuell, Germany) and washed twice with 100 µl 0.1% SDS. For 
analysis of tissue homogenates, 60 µg of total protein for mouse brain and 75 µg of 
total protein for Drosophila heads were filtered per dot. Membranes were blocked 
with 5% skim milk in PBS/0.05% Tween20 (PBS-T) for at least 30 min. Aggregates 
retained on the membrane were detected using GFP, N18, MW8, Mab5492 or HD1 
antibody followed by an appropriate peroxidase-coupled secondary antibody. Signals 
were quantified using the AIDA image analysis software (Raytest, Germany). 
 
Dot blot assays 
To estimate total HTT protein, native dot blot (DB) assays were performed as 
described previously (Kayed et al., 2003). Briefly, 250 ng of Ex1Q48 protein were 
filtered onto a nitrocellulose membrane and blocked with 5% skim milk in PBS-T. For 
detection, the membrane was incubated with HD1 antibody followed by an 
appropriate peroxidase-coupled secondary antibody. Signals were quantified using 
the AIDA image analysis software (Raytest, Germany). 
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Native gels 
Protein solutions were mixed with sample buffer and loaded onto a Novex 
NativePAGE 3-12% Bis-Tris gradient gel (Life Technologies). NativePAGE and 
immunoblotting were performed according to manufacturer recommendations. 
Ex1Q48 aggregates were visualized as for SDS-PAGE.    
 
SDS-PAGE and Western blotting 
Samples of aggregation reactions were mixed with loading buffer (50 mM Tris-HCl 
pH 6.8, 2% SDS, 10% glycerol and 0.1% bromophenol blue) and boiled at 95 °C for 5 
min. Samples were loaded onto Novex NuPAGE 4-12% Bis-Tris gradient gels (Life 
Technologies). SDS-PAGE and immunoblotting were performed according to 
manufacturer recommendations. Ex1Q48 distribution was visualized by N18 antibody 
(Santa Cruz) or Ex1Q48-CyPet/-YPet with a GFP antibody (Abcam) followed by 
appropriate peroxidase labeled secondary antibodies. 
 
Genotyping of Drosophila	strains 
Total genomic DNA from transgenic flies was extracted using the DNeasy® Blood & 
Tissue Kit (Qiagen). cDNAs encoding HTTex1Q17 and HTTex1Q97 were PCR 
amplified using the Pwo DNA polymerase (Roche) and the primers 5’-
aaccccgtaaatcaactgc- 3’ and 5’-atctctgtaggtagtttgtc-3’). The sizes of the resulting 
PCR products were analyzed by agarose gel electrophoresis.	
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Quantitative polymerase chain reaction (qPCR) 
RNA was extracted from Drosophila heads using TRIzol™ Reagent (Invitrogen). 
cDNA was synthesized using M-MLV Reverse Transcriptase (Thermo Scientific) and 
qPCR was performed using the SYBR Green PCR Master Mix (Thermo Scientific). 
Primer pairs for HTT (sense, 5′-gacctggaaaagctgatga-3′ and antisense 5′-
tcatggtcggtgcagcggct-3′), and control primers for rp49 (sense 5′-
tacaggcccaagatcgtgaa-3′, and antisense 5′-acgttgtgcaccaggaactt-3′) were utilized. 
SYBR Green analysis was performed using the ViiA7 Real-time PCR system 
(Thermo Scientific). The amount of mRNA detected was normalized to control rp49 
mRNA values. 
 
Viability analysis of adult Drosophila	melanogaster 
Viability assays were performed with elavGS;HTTex1Q17 and elavGS;HTTex1Q97 
transgenic flies by quantification of lethality of at least 100 females of each genotype 
and expression condition in three independent biological replicates. Flies were aged 
at 25°C, with 10 flies per vial, and were transferred every 3-4 days. Median lifespan 
(age at which half of the tested population has died) was calculated by fitting survival 
curves to the log(inhibitor) vs. normalized response (variable slope) equation using 
GraphPad Prism. Statistical significance was assessed by one-way ANOVA followed 
by Dunnett’s multiple comparison post hoc test. *, p≤0.05; **, p≤0.01; ***, p≤0.001. 
 
Analysis of motor performance (climbing assay) 
	 61	
Ten female flies were placed in a closed empty vial and gently tapped to the bottom 
of the vial. The percentage of flies that climbed 8 cm within 15 s was recorded. Flies 
were aged at 25°C (10 flies per vial) and were monitored and transferred twice a 
week. Motor performance was assessed for elavGS;HTTex1Q17 and 
elavGS;HTTex1Q97 flies expressing the HTT transgenes for the indicated times. 100 
females of each genotype and expression condition in each of the three biological 
replicates were investigated. 
 
Preparation of Drosophila head lysates for FRAs 
Drosophila head lysates were produced by homogenizing fly heads in 2 % SDS and 
complete protease inhibitor cocktail using a micro pestle. Lysates were centrifuged 
for 10 min at 8,000 rpm (4°C). The supernatant was transferred to a new tube and 
total protein concentration was determined with a Pierce™ BCA assay using BSA as 
a standard. 
Dissection and immunostaining of Drosophila adult brain 
The whole brain from adult flies were dissected in ice-cold haemolymph-like saline 
(HL3) solution (Steward et al., 1994), fixed for 20 min in 4 % paraformaldehyde (PFA) 
in PBS and permeabilized in PBS-T (1 % TritonTM X-100) for 20 min at RT. Samples 
were blocked in 10 % normal goat serum (NGS) in PBS-T (0.3 % TritonTM X-100) for 
at least two hours. Brains were incubated with the indicated primary antibody (1:500) 
in brain staining buffer (5 % NGS, 0.1 % NaN3 in PBS-T (0.3 % TritonTM X-100)) for 
48 hours at 4 °C. Subsequently, brains were washed in PBS-T (0.3 % TritonTM X-
100) for 24 hours at 4°C with multiple buffer exchanges. Next, samples were 
incubated with appropriate secondary antibody in brain staining buffer for 24 hours at 
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4 °C, washed six times for 30 min in PBS-T (0.3 % TritonTM X-100) at RT and stored 
in VectaShield (H-100) (Vector Laboratories) at least for one day at -20 °C. Brains 
were mounted and imaged using the Leica TCS SP8 Confocal Microscope. Images 
were analyzed using Fiji. 
 
RNA interference 
For synchronization, gravid adults from one 10 cm NGM plate were collected in a 
canonical tube and treated with 20% alkaline hypochlorite solution under vigorous 
agitation for 4 min. The eggs were then washed three times with cold 0.1 M NaCl 
solution. The eggs were allowed to hatch in M9 medium at 20 °C for 22 h. Animals 
were then placed as L1 larvae onto RNAi plates that were seeded with E. coli 
expressing dsRNAi against hsp-1 or the empty vector L4440 (control).  
 
Fluorescence microscopy 
The aggregation propensities of Q35-YFP were analyzed throughout adulthood. 
Animals were subjected to RNAi treatment from the first larval stage on and 
maintained on RNAi plates throughout the experiment. For imaging, nematodes were 
mounted onto 2% agarose (Sigma) pads on glass slides and immobilized with 2 mM 
Levamisole (Sigma). Images were taken on a Zeiss LSM780 confocal microscope at 
20x magnification. The Q35-YFP expressing nematodes were analyzed as whole 
nematode for quantification of the aggregates and an image was taken of the head 
region of every animal. 20 animals were analyzed for each condition. 
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Motility assay 
Nematodes were transferred from liquid culture onto a blank (unseeded) NGM plate 
and allowed to acclimate for 15 min. The movement of the animals was digitally 
recorded at 20 °C using a Leica M165FC microscope with a DFC3000G digital 
camera and the Leica LASX Software. Movies of 10 s were captured at 10 frames/s. 
Animals that crossed each other or those that escaped from the field of view were 
excluded from analysis. 20 animals were analyzed for each condition. Captured 
frames were merged into *.avi format, imported into Fiji (Schindelin et al., 2012) and 
analyzed using the wrMTrck plugin (http://www.phage.dk/plugins). The average 
speed of each animal was calculated by dividing its body length by the duration of 
each track (body length per second). 
 
Tissue homogenization 
Frozen brain tissue was cut on dry ice, weighed and homogenized in a 10-fold 
excess (w/v) of ice-cold 10 mM Tris-HCl pH 7.4, 0.8 M NaCl, 1 mM EDTA, 10% 
sucrose, 0.25 U/µl benzonase and complete protease inhibitor cocktail with a dounce 
homogenizer. The homogenate was incubated for 1 h at 4 °C on a rotating wheel and 
centrifuged for 20 min at 2,700 x g (4 °C) to remove cell debris. Drosophila heads 
were processed comparably using 10 µl of ice-cold 10 mM Tris-HCl pH 7.4, 0.8 M 
NaCl, 1 mM EDTA, 10% sucrose and a complete protease inhibitor cocktail per fly 
head. Homogenates were centrifuged for 10 min at 8,000 rpm (4°C). After 
centrifugation, supernatants were transferred to a new tube and total protein 
concentration was determined with a Pierce™ BCA assay using BSA as a standard. 
For FRASE analysis, 0.8-5 µg total protein per replicate were applied. 
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Electron microscopy 
Total brain homogenate was centrifuged at 18,000 x g at 4 °C for 20 min; the 
resulting supernatant was pelleted by ultra-centrifugation at 190,000 x g for 40 min 
and resuspended in 10 mM Tris-HCl (pH 7.4). Immunolabeling was performed with 
minor modifications as described (Laue, 2010). Briefly, samples were incubated on 
formvar-coated copper grids (Plano) for 10 min before immunolabeling. Grids were 
blocked and washed in PBS supplemented with 1% BSA and 0.1% glycine. Labeling 
was performed with the anti-HTT aggregate antibody AGG and an appropriate 12 nm 
colloidal gold-labeled secondary antibody (Jackson ImmunoResearch). Samples 
were stained with 2% uranyl acetate and imaged with a Zeiss EM 910 transmission 
electron microscope at 80 kV. Acquisition was performed with a CDD camera 
(Quemesa, Olympus Viewing System); pictures were processed using Adobe 
Illustrator. 
 
Immunodepletion of HTT aggregates from mouse brain extracts 
Protein G-coupled magnetic beads (Life Technologies) were incubated with 4 µg 
MW8 (Developmental Studies Hybridoma Bank, DSHB) or IgG isotype control 
(Invitrogen) antibody, respectively, for 10 min at RT to allow antibody binding. Free 
binding sites were saturated with Pierce protein-free blocking solution according to 
manufacturer recommendations. 500 µg brain homogenate in brain lysis buffer were 
incubated with antibody coupled beads for 3 h at 4 °C under constant overhead 
rotation. Subsequently, aliquots from the supernatants were taken and analyzed with 
the FRASE assay. 
	 65	
 
FRASE assay 
Purified GST-Ex1Q48-CyPet and GST-Ex1Q48-YPet were diluted in aggregation 
buffer at an equimolar ratio to a final concentration of 1.2 µM (0.6 µM each) with 14 U 
PSP per nmol sensor proteins if not stated otherwise. The solution was then mixed 
with preformed aggregates of Ex1Q48 (seeds) at varying concentrations with or 
without prior sonication and transferred to a black 384-well plate (with a final reaction 
volume of 30 µl per well and a sensor protein concentration of 1.2 µM). For 
quantification of seeding-competent HTT species in tissue samples, the sensor-
protein mixture was supplemented with up to 10% (v/v) tissue homogenate. 
Fluorescence signals were measured every 20 min following a 5 s pulse of vertical 
shaking with a Tecan M200 fluorescence plate reader at 25 °C for up to 48 h. CyPet 
donor fluorescence was measured at excitation (Ex): 435 nm/emission (Em): 475 nm; 
YPet acceptor fluorescence at Ex: 500 nm/Em: 530 nm; the FRET channel (DA) was 
recorded at Ex: 435 nm/Em: 530 nm. Raw signals were processed by subtracting the 
background fluorescence of unlabeled Ex1Q48 in all channels. Signals in the FRET 
channel were corrected for donor bleed-through (cD) and acceptor cross excitation 
(cA) using donor- and acceptor-only samples to obtain sensitized emission. Finally, 
sensitized emission was normalized to the acceptor signals (Jiang and Sorkin, 2002). 
In brief, the FRET efficiency E (in %) was calculated as follows: E = (DA-cDxDD-
cAxAA)/AA with DD = donor channel signal and AA = acceptor channel signal. 
 
Quantification of mutant HTT seeding activity (HSA) 
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Seeding effects (Δt50 [h]) were quantified by subtracting the t50 values (time at half-
maximal FRET efficiency) of the respective sample from the negative control. To 
obtain the t50 values, the aggregation kinetics were curve fitted by Richard’s five-
parameter dose-response curve using GraphPad Prism.   
𝑦 = 𝑦! + ( 𝑦! − 𝑦!1+ 10( !"#$%!! ×!"##$#%&')!) 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistical parameters including the exact value of n, the definition of center, 
dispersion and precision measures (mean ± SEM or mean ± SD) as well as the 
statistical analysis chosen and statistical significance are reported in the Figures and 
Figure Legends. Data is judged to be statistically significant when p < 0.05 by the 
indicated statistical test. In figures, asterisks denote statistical significance as 
calculated by Student’s t test (*, p < 0.05; **, p < 0.01; ***, p < 0.001). Statistical 
analysis was performed in GraphPad PRISM 7. 
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